Audited Results and cash dividend declaration for the year ended 30 June 2025 -- 1 of 96 -- 1 Commentary 10 Group statement of financial position 11 Group income statement 12 Group statement of other comprehensive income 13 Group statement of cash flows 14 Group statement of changes in equity A. Notes to the condensed consolidated financial statements 17 A.1. Segment information 26 A.2. Normalised profit from operations 26 A.3. Earnings, headline earnings and normalised headline earnings 28 A.4. Revenue from non-insurance activities 28 A.5. Borrowings at amortised cost 30 A.6. Fair value hierarchy B. Other significant items in these results 34 B.1. Exchange rates to South African Rand used in the preparation of these results 34 B.2. Capital management, financial leverage ratio and covenants 36 B.3. Impact of financial risk variances within the SA Life and UK Life operating segment 36 B.4. Cash and cash equivalents 37 B.5 Consolidation of Discovery Unit trusts 38 B.6. Material transactions with related parties 38 B.7. Major customers and other Discovery entities not part of Discovery Group 38 B.8. Changes in directorate 38 B.9. Events after reporting date and dividend declaration in respect of the year ended 30 June 2025 C. Insurance and reinsurance contract related disclosures 41 C.1.1. Insurance and reinsurance contracts disclosures and reconciliations 45 C.1.2.1 Summary of insurance contracts issued and reinsurance contracts held 46 C.1.2.2 Movement in insurance contract balances: GMM 52 C.1.2.3 Movement in insurance contract balances: VFA 54 C.1.2.4 Movement in reinsurance contract balances: GMM 58 C.1.2.5 Insurance revenue 60 C.1.2.6 Net investment result 64 C.1.2.7 Effect of contracts initially recognised in the period D. Adoption of new standards and interpretations and restatement 68 D.1.1 Restatement as result of prior period errors identified E. Accounting policies 73 E.1. New Accounting Standards and amendments to published Accounting Standards not yet effective 73 E.2. Normalised headline earnings 74 E.3. Basis of preparation Embedded value statement 77 Table 1: Group embedded value 79 Table 2: Value of in-force covered business 79 Table 3: Group embedded value earnings 80 Table 4: Components of Group embedded value earnings 81 Table 5: Experience variances 82 Table 6: Methodology and assumptions changes 83 Table 7: Embedded value of new business 85 Table 8: Embedded value economic assumptions 87 Table 9: Embedded value sensitivity 87 Table 10: Value of new business sensitivity Annexure A 89 New business annualised premium income 90 Income from non-insurance business lines 90 Cash conversion ratio Annexure B 92 Impact of corrections on normalised profit from operations for the six months ended 31 December 2024 93 Administration Contents -- 2 of 96 -- Commentary Discovery Group achieved strong growth across its operations in the year ended 30 June 2025, evidenced by a 29% growth in normalised operating profit to R15 210 million and significant growth in cash conversion, now at 77%. Headline earnings and normalised headline earnings both increased by 30%, to R9 625 million and R9 781 million, respectively, resulting in the normalised return on equity increasing to 15.4%, from 13.5% in the prior year. 1. GROUP OVERVIEW AND SALIENT RESULTS SALIENT GROUP RESULTS FOR THE YEAR ENDED 30 JUNE 2025 The Group delivered a strong performance in an environment characterised by increased geopolitical complexities and uncertainty around global policy shifts and trade tensions. In the year under review, economic growth remained below potential in many regions in which the Group operates, although interest rate reductions provided a better backdrop for investment markets. Risks remain elevated, however the acceleration of technological and demographic trends underpin the relevance of the Vitality Shared-value Insurance model and unique data, positioning the Group uniquely for continued growth. Unit June 2025 June 2024 Change Group earnings1 Normalised profit from operations R million 15 210 11 761 29% Normalised headline earnings R million 9 781 7 511 30% Headline earnings R million 9 625 7 384 30% Basic earnings per share Cents 1 402.2 1 110.3 26% Basic headline earnings per share Cents 1 447.0 1 117.0 30% Basic normalised headline earnings per share Cents 1 470.4 1 136.2 29% Returns, cash conversion and dividends Normalised return on equity (RoE)1 % 15.4 13.5 Annualised return on opening embedded value (RoEV) % 15.7 13.2 Dividend per share for the year Cents 288 217 33% Cash conversion1,2 % 77 65 Growth drivers Income from non-insurance business lines2 R million 6 643 5 906 12% New business annual premium income (API)2 R million 26 486 26 958 (2) % Financial position and embedded value Net asset value1 R million 65 699 54 451 21% Embedded value R million 126 554 110 354 15% Basic embedded value per share R 189.85 166.95 14% Financial leverage ratio (FLR)1 % 16.8 20.3 1 Restated: Refer to D.1.1. 2 Refer to Annexure A; Group new business API increased 8% when excluding Sasolmed in prior year. 11 Commentary Discovery Group achieved strong growth across its operations in the year ended 30 June 2025, evidenced by a 29% growth in normalised operating profit to R15 210 million and significant growth in cash conversion, now at 77%. Headline earnings and normalised headline earnings both increased by 30%, to R9 625 million and R9 781 million, respectively, resulting in the normalised return on equity increasing to 15.4%, from 13.5% in the prior year. 1 -- 3 of 96 -- 1. GROUP OVERVIEW AND SALIENT RESULTS continued STRONG IN-PERIOD PERFORMANCE FROM BOTH COMPOSITES WITH THE GROWTH PHASE UNDERWAY Discovery has emerged strongly from its cycle of significant investment, which focused on creating new avenues for long-term growth. This has positioned the Group for a new distinct phase of scaled organic growth, with focused execution through its recently formed global composite, Vitality, and its domestic business, Discovery South Africa. Over the year, the Group continued to execute its growth strategy, delivering 29% growth in normalised profit from operations. Discovery South Africa delivered 22% growth in normalised profit from operations, reflecting a compelling contribution from each business in South Africa. Vitality generated 70% growth in normalised profit from operations, reflecting the excellent progress made in restructuring all the global operations into a single focused business over the past nine months, and particularly strong growth in the UK. Headline and normalised headline earnings both increased by 30%, delivering a normalised return on equity of 15.4%, up from 13.5% in the prior year. The Group’s embedded value increased to R126.6 billion, a 15.7% return on embedded value (RoEV). This included an increasing contribution from non-covered businesses and robust experience variances over the year, with positive contributions from each business, reflecting the competitive dynamics of the Vitality Shared-value Insurance model. The movement in exchange rates and economic basis assumptions were favourable in aggregate. Total new business API declined 2%, but increased 8% when excluding the large Sasolmed take-on in the prior year, with stronger growth delivered in Vitality. The Group focused on deliberate and disciplined pricing strategies and back-book retention, both leveraging the Vitality Shared-value Insurance model to optimise margins and returns. This has impacted new business growth in some businesses, compounded by macroeconomic challenges. GROWTH PLATFORMS ARE WELL POSITIONED THROUGH UNIQUE DATA AND INVESTMENT IN THE VITALITY SHARED-VALUE INSURANCE MODEL The Group advanced its model by enhancing key value drivers, drawing on technology assets and a rich multi-market, longitudinal dataset that integrates behavioural and operational data. The group-wide application of artificial intelligence (AI) harnesses this data not only to drive efficiency, but also to transform risk prediction and engagement, delivering measurable improvements in health outcomes, service delivery, and profitability. Discovery AI has been launched to Discovery Bank customers and Vitality AI has been launched as Personal Health Pathways (PHP) in SA, allowing more precise understanding of health risks and hyper-personalised product experiences to encourage healthier behaviour. Both capabilities have driven excellent customer engagement and outcomes. THE GROUP IS FINANCIALLY RESILIENT IN A COMPLEX AND UNCERTAIN ENVIRONMENT Capital ratios remained strong across every regulated business and liquidity at each regulated entity, as well as at the centre, remained well in excess of the required buffers. Debt across the Group decreased over the year and the FLR reduced to 16.8%. Ping An Health Insurance (PAHI) paid its second consecutive annual dividend, at a 35% payout ratio (previously 30%), and the Group’s cash conversion ratio increased to 77% of after-tax normalised operating profit, compared with 65% in the prior year, notwithstanding the strong growth in normalised profit from operations. SUMMARY OF PROFIT FROM OPERATIONS AND NEW BUSINESS PERFORMANCE BY COMPOSITE FOR THE CURRENT PERIOD: R million Normalised profit from operations % change New business API % change Discovery Health 4 259 7% 9 573 (14%) Discovery Life1 5 525 14% 3 203 (10%) Discovery Invest 1 987 29% 3 430 4% Discovery Insure 817 229% 1 361 (2%) Discovery Bank (68) (85%) Other initiatives and central costs (515) 91% 546 33% Discovery SA composite 12 005 22% 18 113 (8%) VitalityHealth 1 188 173% 2 851 3% VitalityLife 637 70% 2 499 28% Vitality Network 554 4% Ping An Health Insurance (PAHI) 1 206 7% 3 023 22% Vitality Health International (VHI) Other (291) (25%) Other initiatives and central costs2 (89) (54%) Vitality (UK and VG) composite 3 205 70% 8 373 16% Normalised profit from operations 15 210 29% New business API1,3 26 486 (2%) 1 Discovery Life: Individual Life new business API declined 2%. 2 Includes closure costs of VitalityInvest in the prior year. 3 Group new business API increased 8% when excluding Sasolmed in prior year. Commentary continued 2 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 4 of 96 -- 2. BUSINESS-SPECIFIC PERFORMANCE DISCOVERY SOUTH AFRICA Discovery SA increased normalised operating profit by 22% to R12 005 million. New business volumes increased by 5%, adjusting for the prior year take-on of the Sasolmed closed medical scheme (declined 8% including Sasolmed), and market shares of the established businesses were broadly maintained with a focus on quality and risk-based pricing discipline. Discovery Bank (DB) continued to expand its capabilities, innovative product solutions and quality customer base, with more than two-thirds of new bank customers being new to the Group. DB is a key strategic platform to drive further growth through Discovery SA’s 6.4 million customer base, which increased 6%. The composite’s strong performance was supported by excellent levels of customer engagement, which drove strong claims experience and retention across the franchise. A resulting increased Vitality benefit utilisation, and successful launch of the new HealthyFood partner, added to various additional one-off costs at the centre, both of which are expected to ameliorate in FY2026. DISCOVERY BANK Unit June 2025 June 2024 % Change Net non-interest revenue (NIR)1 R million 1 373 1 039 32% Net Interest income (NII)2 R million 1 017 780 30% Operating profit before new business acquisition costs R million 368 (52) >100% Normalised profit/(loss) from operations R million (68) (454) 85% Retail deposits R billion 23.3 18.5 26% Advances R billion 9.2 6.6 39% Average interest-earnings assets (IEA)2 R billion 24.6 19.5 26% Credit loss ratio (CLR)3 % 3.03 2.78 31% Number of accounts Million 3.00 2.27 32% Number of clients Million 1.25 0.96 30% 1 Segment refinements: Refer to A.1. 2 NII Includes the allocation of interest earned on the bond trading portfolio (recognised at fair value gains in the income statement); Average interest-earning assets (IEA) = treasury assets + retail banking activities. 3 CLR calculated as the expected credit loss (ECL) charge, including overlays and IFRS adjustments, on the year-end advances balance across the products. Discovery Bank (DB) improved its operating loss before new business acquisition costs by R420 million, and the overall loss was R386 million better than the prior year. DB reached monthly break-even at the end of H1 and generated its first profitable period during the second half of the financial year, ahead of plan. DB’s total client base grew 30% to June 2025, reaching 1 400 daily sales in June. DB remained focused on high-quality growth, which manifested in strong growth across key operational metrics. Non-interest revenue increased by 32%, driven by the growth in clients, as well as increased engagement levels and product take-up, driving up the resulting fee income per client for each cohort. Deposits increased by 26% and advances by 39%, with NII (including interest on bonds) 30% higher. The Revolving Credit Facility product more than doubled since the prior year and home loans grew significantly to R1.7 billion at June 2025. Personal loans for existing clients went live on 30 June 2025, with seamless application and management through the Discovery Bank app. Commentary continued 3 -- 5 of 96 -- 2. BUSINESS-SPECIFIC PERFORMANCE continued DISCOVERY HEALTH Unit June 2025 June 2024 % Change Normalised profit from operations R million 4 259 3 972 7% New business API1 R million 9 573 11 069 (14%) Revenue2 R million 11 888 10 841 10% Non-scheme revenue as % of total revenue % 15.8 13.5 –% Lives under administration Million 3.98 3.92 1% 1 Prior year API includes Sasolmed take on. New business API increased 12% excluding Sasolmed take on. 2 Segment refinements: Refer to A.1. Discovery Health (DH) operating profit grew by 7% while continuing to invest in technology and artificial intelligence. Since its launch in January 2025, Personal Health Pathways (PHP) achieved over 330,000 activations, demonstrating strong forward momentum of the Vitality AI-powered platform. Non-medical scheme products remain a key growth driver, with non-scheme revenue now comprising 16% of total DH revenue – highlighting the opportunity in adjacent offerings. DHMS demonstrated resilience in a low-growth open medical scheme market and challenging macroeconomic environment, increasing its market share to 58%. Projected 2025 solvency of 32%, is well above the 25% regulatory requirement. DISCOVERY LIFE Unit June 2025 June 2024 % Change Normalised profit from operations1,2 R million 5 525 4 838 14% New business API2 R million 3 203 3 568 (10%) Premium income R million 19 001 17 892 6% Insurance revenue (IFRS 17) R million 19 149 17 522 9% Solvency ratio3 % 192 183 RoEV3 % 15.7 14.3 VNB margin % 2.1 3.8 New business net value4 R million 1 460 1 686 (13%) 1 Restated: Refer to D.1.1. 2 Includes Group Risk and Umbrella (part of Corporate and Employee Benefits (CEB)) offerings. 3 Including Discovery Invest. 4 Calculated as: New business contractual service margin (CSM) + risk adjustment (RA) minus onerous new business. Discovery Life’s (DL) operating profit increased by 14% to R5 525 million. Both the Individual Life (+11%) and Corporate and Employee Benefits (+71%) businesses delivered exceptional claims performances, contributing to a c. R580 million lower claims expense for DL than the prior year. This offset a significant reduction in the insurance finance income and expense (IFIE), which was impacted by the lower systematic interest rates reset at the start of the financial year. The Discovery Life Limited embedded value (including Discovery Invest) delivered an annualised RoEV of 16%, driven by positive variances and lower interest rates at the end of the year. Claims experience, in particular, delivered a significant positive variance to the embedded value. The business remains focused on managing the negative policy alterations experience and is phasing in a well- defined mitigation strategy. Individual Life new business API volumes decreased 2% while Corporate and Employee Benefits decreased 41% in a competitive market. DL prioritised quality of business and maintained its leading position in the affluent retail protection market with a market share of 27%. Within DL’s 2.1% VNB margin, the Individual Life margin decreased to 3.8%, previously 5.0%, primarily due to the lower new business volumes. Discovery Life maintained strong solvency and liquidity positions, with a solvency coverage ratio of 192% and liquidity coverage in excess of 200%. DL cash generation (including Discovery Invest) was exceptionally strong, increasing to R3 327 million (prior year R2 193 million), before a R1 566 million net repayment of financing arrangements (prior year R495 million). The updated economic position referencing market yield curves at 30 June 2025 results in a lower implied future inflation rate and in turn a lower systematic interest rate. This will mechanically lead to the interest accretion through IFIE in FY2026 being c. R160 million lower compared with FY2025, all else being equal. Commentary continued 4 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 6 of 96 -- DISCOVERY INVEST Unit June 2025 June 2024 % Change Normalised profit from operations1,2 R million 1 987 1 539 29% Assets under administration R billion 179 155 15% Assets under management R billion 124 105 18% % linked assets in Discovery funds % 80 80 Net client cash flows R billion 3.2 3.1 3% New business API R million 3 430 3 300 4% 1 Restated: Refer to D.1.1. 2 Segment refinements: Refer to A.1, with the presentation of certain policyholder tax now better reflected in both the operating profit and the tax result. Discovery Invest increased operating profit by 29%. Assets under management grew by 18% and assets under administration grew by 15% due to the strong market performance. Profit for the year was boosted by R85 million of asset liability matching gains reported in December and a R129 million release of a reserve for tax recoveries from policyholders, accrued over prior years. New business API increased 4%. A 21% decrease in sales of guaranteed plans, reflecting lower market interest rates, was offset by a 9% increase from all other products, demonstrating product diversity. Net client cash flows increased, curtailed somewhat by a large maturing book of five-year guaranteed endowments sold during the beginning of COVID-19, when market rates increased. DISCOVERY INSURE Unit June 2025 June 2024 % Change Discovery Insure normalised profit from operations R million 739 199 Equity accounted profit /(loss) R million 78 49 Normalised profit from operations R million 817 248 229% Operating margin % 11.9 3.5 New business API R million 1 361 1 388 (2%) Insurance revenue R million 6 217 5 737 8% Discovery Insure sustained its positive trajectory over the year, delivering an operating profit of R739 million. The operating margin of 11.9% reflects disciplined execution and effective cost management, with lower new business volumes influenced by the deliberate pricing strategies and evolving market dynamics. The performance highlights the success of targeted management actions, particularly in improving non-weather-related claims experience, which showed further gains in the second half of the financial year. In addition, benign weather conditions in the current year, in comparison to severe weather in the prior year, resulted in the loss ratio being 2.5% lower than expected. Commentary continued 5 -- 7 of 96 -- 2. BUSINESS-SPECIFIC PERFORMANCE continued VITALITY (UNITED KINGDOM AND VITALITY GLOBAL) Vitality‘s normalised operating profit increased by 70% to R3 205 million and new business API increased by 16% to R8 373 million. Excellent progress was made in restructuring all the global operations into a single focused business over the past nine months to effectively deploy the capabilities, including Vitality AI. This is being executed through a regionalised operating model to efficiently scale the business with operational leverage. Vitality now covers 10.4 million lives outside of China, up 25% over the year, including more than two million customers in the UK. PAHI’s lives increased 17%, exceeding 32 million. VITALITY HEALTH Unit June 2025 June 2024 % Change Normalised profit from operations £ million 50.6 18.5 174% R million 1 188 435 173% Insurance revenue (earned premiums) £ million 815 699 16% R million 19 124 16 474 16% New business API1 £ million 121 118 3% R million 2 851 2 779 3% Lives covered Million 1.06 1.03 3% 1 Refer to Annexure A. VitalityHealth’s (VH) operating profit rose by 174% to £50.6 million (173% to R1 188 million), driven by effective pricing actions, a stabilising claims environment and rigorous claims and expense management. The pricing actions addressed the elevated PMI utilisation following sustained pressures in the NHS, with premiums now fully aligned to claims experience in support of margin recovery. Advanced price optimisation and a diversified distribution capability supported a 3% increase in new business, notwithstanding the significant premium increases and challenging macroeconomic environment. Strong retention, particularly of healthier members, driven by the Vitality programme benefits and the perceived value of PMI cover, contributed to a 16% rise in earned premiums. VH also continued its strategic investment in healthcare risk management, primary care assets, and digital servicing to enhance cost efficiency and care outcomes. Commentary continued 6 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 8 of 96 -- VITALITY LIFE Unit June 2025 June 2024 % Change Normalised profit from operations £ million 27.1 15.9 70% R million 637 375 70% Earned premiums £ million 448 402 11% R million 10 514 9 464 11% New business API £ million 106 83 28% R million 2 499 1 956 28% Insurance revenue £ million 343 293 17% R million 8 050 6 904 17% Lives covered Million 0.904 0.810 12% VNB margin % 0.2 (1.3) New business net value1 £ million 46.9 16.1 191% R million 1 142 371 207% 1 New business net value (NB CSM + NB RA minus onerous NB) excludes the impact of new reinsurance contracts attaching to the in-force book in the year. The total CSM and RA on all contracts incepted in the year was £52.1 million (R1 268 million) VitalityLife’s (VL) operating profit recovered strongly, increasing 70% to £27.1 million (70% to R637 million), with stable lapse and claims experience reflecting sustained member engagement in the Vitality programme and its positive impact on actuarial dynamics. VL maintained its positive sales trajectory from the second half of the previous year, with new business increasing by 28% on an API basis and by 44%, excluding automatic contribution increases. The UK market demonstrated early signs of growth, supported by competitor consolidation, and VL continued to drive effective execution of the Vitality Shared-value Insurance model through an expanded distribution footprint to deliver strong new business growth and enhanced quality. Coupled with disciplined expense management, these actions resulted in a significant improvement in new business net value. The robust retention and strong new business saw lives covered and earned premiums increase by 12% and 11%, respectively. VITALITY GLOBAL VITALITY NETWORK Unit June 2025 June 2024 % Change Revenue US$ million 109 101 8% R million 1 977 1 894 4% Normalised profit from operations US$ million 30.5 28.5 7% R million 554 533 4% Operating margin % 28 28 Integrated API by Insurance Partners US$ million 1 951 1 575 24% R million 35 423 29 673 20% Number of lives Million 6.66 5.25 27% Vitality Network’s (VN) normalised operating profit increased by 7% to US$30.5 million (4% to R554 million). Vitality-integrated new business increased 24%, to c. US$2 billion, driving performance-based revenues up 24%. Lower solutions revenues resulted in total revenues increasing only 8%. The operating margin remained unchanged at 28%, following additional expenditure during the year. Membership increased by 27% to 6.7 million demonstrating the strong global relevance of the Vitality Shared-value Insurance model. Following the establishment of the global Vitality composite, VN restructured its operating model and partnerships to further monetise its unique global position to deliver scaled growth and operational leverage. In particular, the partnership with Generali was terminated, opening up the large European markets. VN will also be investing further alongside AIA to drive even deeper engagement and value from the successful long-standing partnership, with some short-term impact on our costs. Commentary continued 7 -- 9 of 96 -- 2. BUSINESS-SPECIFIC PERFORMANCE continued PING AN HEALTH INSURANCE (PAHI) Annual results DSY PAHI half-year (6-month) period2 Unit June 2025 June 2024 % Change June 2025 June 2024 % Change PAHI after-tax operating profit (25%), after Discovery’s costs R million 1 206 1 124 7% 782 780 0% New business (100%)1 RMB million 4 807 3 842 25% 3 064 2 251 36% New business (25%)1 R million 3 023 2 486 22% 1 935 1 459 33% Earned premium (100%)1 RMB million 17 807 14 747 21% 9 521 7 617 25% Earned premium (25%)1 R million 11 201 9 543 17% 6 028 4 939 22% Lives1 Million 32.1 27.4 17% Profit before investment income and gains (100%) RMB million 1 398 1 470 (5%) 1 092 1 114 (2%) Investment income and gains (100%) RMB million 1 146 621 84% 547 419 30% PAHI pre-tax profit (100%) RMB million 2 544 2 092 22% 1 638 1 533 7% 1 PAHI own licence business. 2 PAHI half-year calendar performance has been included to align with the Chinese industry comparable reporting The Group’s share of PAHI’s after-tax operating profit increased by 7% to R1 206 million, following the prior year’s exceptional result that benefited from both a tax gain (December 2023) and a significant COVID-19 reserve release (March 2024). Profit before investment income and gains declined 5%, however increased when adjusting for the COVID-19 reserve release, demonstrating the improved underlying performance. PAHI’s pre-tax result increased by 22%, following continued gains from Chinese bond and equity markets, delivering a robust net margin of 11% for the financial year (14% for PAHI’s interim results to June 2025). New business increased by 22% to R3 023 million (Discovery’s 25% share) for the year, driven by a rise in new business through non-Ping An Life channels and a general market shift towards higher-end products. This growth reflects PAHI’s continued investment in product innovation and the expansion of distribution beyond traditional channels. Insured lives increased by 17%, reaching 32.1 million, with earned premiums also growing 17% over the 12-month period, outpacing the industry significantly. PAHI’s comprehensive solvency ratio increased to 334% in Q2 2025 (from 319% in Q2 2024), reflecting continued capital strength and prudent capital management. Discovery received a cash dividend of RMB166 million in June 2025 (RMB102 million in the prior year), representing the Group’s share of a 35% dividend payout. VHI OTHER Losses in VHI Other improved 25% to R291 million, following lower losses in Vitality USA and the successful integration of WellSpark Health, a personalised coaching business acquired in November 2024. Vitality USA made significant progress in shifting its focus from the traditional employee wellness market towards the significantly larger market of integrated digital health and care. It has developed a broad set of customised wellbeing, coaching, and disease prevention services, and will be deploying Vitality AI to EmblemHealth, New York’s leading health plan provider, in January 2026. The business continues to make progress in its sales to health plans, including to BlueCross BlueShield plans, and to the significant Medicare Advantage market. Amplify Health continued its delivery of products and solutions within the Asia-Pacific region. The business had successful deployments in multiple Asia-Pacific markets, across all its main products, including its core claims system, and is prioritising the deployment of an integrated suite of products to the key markets. Amplify Health received three prestigious awards during the past year, recognising its achievements in developing advanced health technology services in the Asia-Pacific region. Commentary continued 8 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 10 of 96 -- PROSPECTS AND DIVIDEND Discovery’s growth strategy is based on the efficacy, repeatability, and scalability of its model through organic growth and global partnerships. The Group is well positioned for sustained growth after a phase of investment in its two powerful and focused composites; Discovery South Africa and Vitality, with strong platforms in each, resulting in growth in earnings, cash generation, and return on equity, as well as lower leverage. The Group established a five-year ambition for profit from operations to grow between 15% to 20% on a compound basis from the end of 2024 to 2029. The strong performance in the first year of delivery has increased the Group’s confidence in achieving this ambition over the period. In terms of the Group’s current dividend policy and guidance, annual ordinary dividends are expected to be covered approximately five times by normalised headline earnings, with interim ordinary dividends expected to be paid in the range of 30% to 40% of the expected total annual ordinary dividend. In line with this, the Group has declared its final ordinary dividends for the period at 201 cents per share, representing an annual cover ratio of 5 times. NOTES TO ANALYSTS Any forecast financial information contained in this announcement has not been reviewed or reported on by the Company's external auditors. Discovery has published supplemental unaudited information on the website. For this and other results information, visit https://www.discovery.co.za/corporate/investor-relations and go to Financial and annual reports. On behalf of the Board ME Tucker A Gore Chairperson Group Chief Executive Sandton 10 September 2025 Commentary continued 9 -- 11 of 96 -- R million Group 2025 Restated Group 20241 Restated Group 1 July 20231 Assets Goodwill 5 429 5 292 5 406 Intangible assets 7 542 7 239 7 064 Property and equipment 3 266 3 581 3 910 Assets arising from insurance contracts issued 48 047 37 339 30 224 Assets arising from reinsurance contracts held 962 837 604 Deferred tax asset 4 886 5 631 6 370 Assets arising from contracts with customers 3 722 2 598 2 221 Investment in equity-accounted investees 8 989 8 189 7 398 Financial assets – Loans and advances to customers at amortised cost 8 513 6 028 4 702 – Investments at amortised cost 12 812 11 100 9 910 – Investments at fair value through other comprehensive income 14 – – – Investments at fair value through profit or loss 193 776 165 671 152 515 – Derivative financial instruments at fair value through profit or loss 63 43 119 Contract receivables and other receivables 7 368 6 729 5 684 Non-current assets held for sale 62 136 – Current tax asset 31 250 41 Cash and cash equivalents 21 968 18 971 19 171 TOTAL ASSETS 327 450 279 634 255 339 Equity Capital and reserves Ordinary share capital and share premium 11 358 10 667 10 351 Perpetual preference share capital 779 779 779 Other reserves 4 921 2 176 1 562 Retained earnings 48 646 40 829 34 546 Equity attributable to equity holders of the Company 65 704 54 451 47 238 Non-controlling interest (5) – 4 TOTAL EQUITY 65 699 54 451 47 242 Liabilities Liabilities arising from insurance contracts issued 118 878 105 070 94 660 Liabilities arising from reinsurance contracts held 9 121 5 396 4 819 Deferred tax liability 8 755 6 975 5 788 Contract liabilities to customers 1 516 512 656 Third-party interest in consolidated funds 35 932 31 456 28 346 Financial liabilities – Borrowings at amortised cost 20 046 21 662 20 586 – Other financial payables at amortised cost 9 148 8 007 8 568 – Deposits from customers 23 326 18 467 14 333 – Investment contracts at fair value through profit or loss 32 188 25 710 28 903 – Derivative financial instruments at fair value through profit or loss 135 31 20 Provisions – 449 187 Other payables 2 333 1 216 1 066 Current tax liability 373 232 165 TOTAL LIABILITIES 261 751 225 183 208 097 TOTAL EQUITY AND LIABILITIES 327 450 279 634 255 339 1 The comparative information has been restated due to correction of a prior period error. Refer to note D.1.1 for more detail. Group statement of financial position for the year ended 30 June 2025 10 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 12 of 96 -- R million Group 2025 Restated Group 20241 Insurance revenue 57 713 52 130 Insurance service expenses (49 028) (46 117) Net expenses from reinsurance contracts (1 306) (915) Insurance service result 7 379 5 098 Net financial result from insurance finance income and expense (13 088) (7 293) – Net finance expense from insurance contracts (12 665) (6 950) – Net finance expense from reinsurance contracts (423) (343) Investment income using the effective interest rate method 998 860 Net fair value gains on financial assets at fair value through profit or loss 25 818 16 245 Fair value adjustment to liabilities under investment contracts (3 810) (2 142) Third party interest: fair value adjustment to liabilities under investment contracts (4 394) (2 873) Other gains on financial instruments (9) 5 Net insurance and investment results 12 894 9 900 Fee income from administration businesses 14 326 13 596 Vitality income 5 322 4 655 Net banking fee and commission income 1 695 1 398 – Banking fee and commission income 2 238 1 872 – Banking fee and commission expense (543) (474) Net bank interest and similar income 966 779 – Bank interest and similar income using the effective interest rate 2 203 1 840 – Bank interest and similar expense using the effective interest rate (1 237) (1 061) Other income 1 832 1 380 Non-insurance revenue and income 24 141 21 808 Net income 37 035 31 708 Non-insurance acquisition costs (384) (491) Expected credit losses (279) (183) Marketing and administration expenses (21 765) (19 644) Impairment of goodwill (20) – Operating profit 14 587 11 390 (Loss)/gain on dilution and disposal of equity-accounted investments (32) 22 Share of net profits from equity-accounted investments 1 215 975 Profit before financing and income tax 15 770 12 387 Interest expenses on borrowings and lease liabilities (2 087) (2 036) Foreign exchange (losses) (36) (87) Profit before income tax 13 647 10 264 Income tax expense (4 089) (2 715) Profit for the year 9 558 7 549 Profit attributable to: – Ordinary shareholders 9 471 7 468 – Preference shareholders 93 91 – Non-controlling interest (6) (10) 9 558 7 549 Earnings per share for profit attributable to ordinary shareholders of the company during the year (cents): – Basic 1 402.2 1 110.2 – Diluted 1 394.9 1 103.7 1 The comparative information has been restated due to correction of a prior period error. Refer to note D.1.1 for more detail. Group income statement for the year ended 30 June 2025 11 Results commentary Group statement of financial position Group income statement Group statement of other comprehensive income Group statement of cash flows Group statement of changes in equity Notes to the condensed consolidated financial statements Other significant items in these results Insurance and reinsurance contract related disclosures Restatements Accounting policies Embedded value statement Annexure A Administration -- 13 of 96 -- R million Group 2025 Restated Group 20241 Profit for the year 9 558 7 549 Income and expenses that will be reclassified to profit or loss when specific conditions are met: Currency translation differences 998 (823) Unrealised gains/(losses) 1 032 (846) Tax on unrealised (gains)/losses (34) 23 Cash flow hedges (104) (61) – Unrealised losses (106) (65) – Gains reclassified to profit or loss 2 4 Net finance income/(expense) from insurance contracts issued 2 186 1 701 – Unrealised income/(expense) 2 961 2 265 – Tax on unrealised (income)/expense (775) (564) Net finance (expense)/income from reinsurance contracts held (282) (221) – Unrealised (expense)/income (382) (290) – Tax on unrealised expense/(income) 100 69 Share of other comprehensive income from equity-accounted investments (120) (236) – Change in fair value of debt instruments at fair value through other comprehensive income 16 45 – Currency translation differences (136) (281) Total income and expenses that will be reclassified to profit or loss when specific conditions are met 2 678 360 Income and expenses that will not be reclassified to profit or loss: Equity instruments held at fair value through other comprehensive income (2) – – Change in fair value of equity instruments at fair value through other comprehensive income (2) – – Tax on change in fair value of equity instruments at fair value through other comprehensive income * – Share of other comprehensive (loss)/income from equity-accounted investments 23 17 – Change in fair value of equity instruments at fair value through other comprehensive income 23 17 Total income and expenses that will not be reclassified to profit or loss 21 17 Other comprehensive income for the year, net of tax 2 699 377 Total comprehensive income for the year 12 257 7 926 Attributable to: – Ordinary shareholders 12 169 7 839 – Preference shareholders 93 91 – Non-controlling interest (5) (4) Total comprehensive income for the year 12 257 7 926 1 The comparative information has been restated due to correction of a prior period error. Refer to note D.1.1 for more detail. * Amount is less than R500 000. Group statement of other comprehensive income for the year ended 30 June 2025 12 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 14 of 96 -- R million Group 2025 Restated Group 20241 Cash flows from operating activities 8 667 2 733 Cash generated from operations 1 289 3 976 Interest received 2 955 2 325 Interest paid (2 877) (2 627) Taxation paid (1 867) (1 522) Net movement in operating assets and liabilities 9 167 581 – Increase in operating assets (11 060) (3 224) – Increase in operating liabilities 20 227 3 805 Cash flows from investing activities (1 823) (1 886) Purchase of property and equipment (294) (414) Proceeds from disposal of property and equipment 3 29 Purchase of intangible assets (1 682) (1 789) Acquisition of business and subsidiaries net of cash (316) – Additional investment in equity-accounted investments (24) (17) Dividends from equity-accounted investments 490 305 Cash flows from financing activities (4 016) (780) Purchase of treasury shares – (131) Dividends paid to ordinary shareholders (1 614) (1 178) Dividends paid to preference shareholders (93) (91) Proceeds from borrowings 3 264 2 005 Repayment of borrowings (5 573) (1 385) Net increase in cash and cash equivalents 2 828 67 Cash and cash equivalents at beginning of the year 18 965 19 138 Effects of exchange rate changes on cash and cash equivalents 173 (240) Cash and cash equivalents at end of the year 21 966 18 965 Reconciliation to statement of financial position Cash and cash equivalents 21 968 18 971 Bank overdraft included in borrowings at amortised cost (2) (6) Cash and cash equivalents at end of the year 21 966 18 965 1 The comparative information has been restated due to correction of a prior period error. Refer to note D.1.1 for more detail. Group statement of cash flows for the year ended 30 June 2025 13 Results commentary Group statement of financial position Group income statement Group statement of other comprehensive income Group statement of cash flows Group statement of changes in equity Notes to the condensed consolidated financial statements Other significant items in these results Insurance and reinsurance contract related disclosures Restatements Accounting policies Embedded value statement Annexure A Administration -- 15 of 96 -- R million Attributable to equity holders of the Company Share capital and share premium Perpetual preference share capital Share-based payment reserve Investment reserve1 Year ended 30 June 2025 At beginning of the year 10 667 779 1 433 81 Total comprehensive income for the year – 93 – 37 Profit for the year – 93 – – Other comprehensive income – – – 37 Transactions with owners 691 (93) 47 – Share issue 626 – – – Increase in treasury shares (626) – – – Delivery of treasury shares 691 – (674) – Employee share option schemes: – Value of employee services, net of tax – – 721 – Dividends paid to preference shareholders – (93) – – Dividends paid to ordinary shareholders – – – – At end of the year 11 358 779 1 480 118 Year ended 30 June 2024 At beginning of the year 10 351 779 1 190 19 - Prior period error adjustments2 – – – – Restated balance at beginning of the year 10 351 779 1 190 19 Total comprehensive income for the year – 91 – 62 Profit for the year – 91 – – Other comprehensive income – – – 62 Transactions with owners 316 (91) 243 – Share issue 432 – – – Increase in treasury shares (563) – – – Delivery of treasury shares 447 – (440) – Employee share option schemes: – Value of employee services, net of tax – – 683 – Dividends paid to preference shareholders – (91) – – Dividends paid to ordinary shareholders – – – – At end of the year 10 667 779 1 433 81 1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt instruments measured at FVOCI, in terms of IFRS 9 Financial Instruments. 2 The comparative information has been restated due to correction of a prior period error. Refer to section D1.1 for more detail. Group statement of changes in equity for the year ended 30 June 2025 14 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 16 of 96 -- Attributable to equity holders of the Company Insurance finance reserve Foreign currency translation reserve Hedging reserve Retained earnings Total Non- controlling interest Total Equity (4 832) 5 514 (20) 40 829 54 451 – 54 451 1 904 861 (104) 9 471 12 262 (5) 12 257 – – – 9 471 9 564 (6) 9 558 1 904 861 (104) – 2 698 1 2 699 – – – (1 654) (1 009) – (1 009) – – – (23) 603 – 603 – – – – (626) – (626) – – – (17) – – – – – – – 721 – 721 – – – – (93) – (93) – – – (1 614) (1 614) – (1 614) (2 928) 6 375 (124) 48 646 65 704 (5) 65 699 (3 184) 6 624 41 33 900 49 720 4 49 724 (3 128) – – 646 (2 482) (2 482) (6 312) 6 624 41 34 546 47 238 4 47 242 1 480 (1 110) (61) 7 468 7 930 (4) 7 926 – – – 7 468 7 559 (10) 7 549 1 480 (1 110) (61) – 371 6 377 – – – (1 185) (717) – (717) – – – – 432 – 432 – – – – (563) – (563) – – – (7) – – – – – – – 683 – 683 – – – – (91) – (91) – – – (1 178) (1 178) – (1 178) – – (4 832) 5 514 (20) 40 829 54 451 – 54 451 15 -- 17 of 96 -- SECTION A NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 17 A.1 Segment information 26 A.2 Normalised profit from operations 26 A.3 Earnings, headline earnings and normalised headline earnings 28 A.4 Revenue from non-insurance activities 28 A.5 Borrowings at amortised cost 30 A.6 Fair value hierarchy 16 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 18 of 96 -- A.1 SEGMENT INFORMATION Discovery’s operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker (CODM). The CODM has been identified as the Group Executive Committee who makes strategic decisions regarding these businesses. An operating segment is a component of an entity: (a) That engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses relating to transactions with other components of the same entity. (b) Whose operating results are regularly reviewed by the entity’s CODM to make decisions about resources to be allocated to the segment and assess its performance; and (c) For which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. Discovery will report separately information about an operating segment that meets any of the following quantitative thresholds: (a) Its reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 percent or more of the combined revenue, internal and external, of all operating segments. (b) The absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount, of (i) the combined reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all operating segments that reported a loss; and (c) Its assets are 10 percent or more of the combined assets of all operating segments. Operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed, if management believes that information about the segment would be useful to users of the financial statements. Discovery may combine information about operating segments that do not meet the quantitative thresholds with information about other operating segments that do not meet the quantitative thresholds to produce a reportable segment only if the operating segments have similar economic characteristics. The Group has identified its reportable segments based on a combination of products and services offered to customers and the location of the markets served. Disclosure for the year ended 30 June 2025 A. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 17 -- 19 of 96 -- A.1 SEGMENT INFORMATION continued The following summary describes the operations of each of the Group’s reportable segments: A. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS continued 18 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 SA HEALTH ■ Administers and provides managed care services to medical schemes in South Africa. ■ Renders administration services to other business segments within the Group. ■ Together with Medical Services Organisation International (MSO), a subsidiary company, delivers health insurance, healthcare risk management and third-party administration services within rest of Africa markets. ■ Offers non-medical scheme-related products such as Gap Cover for unexpected medical costs and Flexicare – which provides quality, affordable access to primary healthcare for employees unable to access medical scheme benefits. SA INVEST Offers, through a range of investment fund choices, including Discovery managed unit trusts, a comprehensive and flexible range of investment choices. These products are sold through a number of investment wrappers, including Discovery Life policies, and are offered to individuals in South Africa. SA LIFE Offers a range of insurance and financial solutions to the Group’s clients against the financial impact of lifestyle-changing events in South Africa. This segment also includes Corporate and Employee Benefits (CEB), which comprises the Group Risk, Umbrella and HealthyCompany offerings. SA INSURE Offers a range of personal line insurance (motor, building, household content and portable possessions) to the Group’s SA clients against the financial impact of loss or damage. The segment also includes SA Insure’s equity-accounted interests including Cambridge Mobile Telematics (CMT). SA BANK Offers retail banking solutions, including deposits and loans and advances, to clients in the South African market. The Bank is still in a start-up phase. UK HEALTH Offers consumer-engaged private medical insurance products to employer groups and individuals in the UK. All contracts in this segment are short-term insurance contracts. UK LIFE Offers a risk-only life assurance product. All contracts in this segment are long-term assurance contracts offered to both employer groups and individuals in the UK. Includes those businesses that are not operating segments, as well as those operating segments that do not meet the qualitative thresholds for separate reporting. It includes: Discovery SA: – SA Vitality, which offers health and lifestyle benefits with selected partners to the Group’s SA clients. – SA Insure commercial: provides commercial short-term risk insurance products to the South African market. Discovery announced that it is exiting this business with all remaining covers terminated by 31 August 2024. – SA Distribution: provides sales and distribution services in respect of all SA products. – Discovery Central Services, performing various shared services, treasury and administrative functions to entities within the Discovery Group. – Other new group initiatives, including Discovery Green, as well as unallocated central costs. Vitality: – Vitality Corporate Services (VCSL): provides administration, distribution and management services for entities within the UK Composite. – Vitality Health International, leverages Discovery Health and Vitality’s intellectual property to create strategic partnerships through equity-accounted interests in health insurance and health technology and solutions businesses, which includes the equity-accounted interests in Ping An Health Insurance and Amplify Health. – Vitality Network, which provides a Vitality platform to international insurance businesses. – Includes immaterial interests in equity-accounted interests, UK Invest (closed down), as well as unallocated central costs. -- 20 of 96 -- A.1 SEGMENT INFORMATION continued The Group Executive Committee assesses the performance of the reportable segments based on normalised profit/loss from operations. Items that are excluded from normalised profit/loss from operations are separately disclosed in the segment information to reconcile to the segment results and Group income statement. The segment information is presented on the same basis as reported to the CODM. The segment total is then adjusted for accounting reclassifications and entries required to produce results compliant with the IFRS Accounting Standards, i.e. IFRS reporting adjustments. These adjustments include the following: (a) Unit trusts that the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into Discovery’s results for IFRS purposes. The IFRS reporting adjustments include the effects of consolidating the unit trusts into Discovery’s results, effectively being the income and expenses relating to units held by third parties. (b) The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments; and (c) The effects of reclassifying items to align to the IFRS Group income statement. Changes from 1 July 2024 1. In response to the IFRIC decision on the presentation of material items of revenue and expenses for segment information, Discovery’s internal enhancements to financial reporting, and observations from the JSE Proactive Monitoring process, Discovery Group has expanded its segment disclosure. In particular, the adjustments take into account the information reviewed by the CODM as well as the required disclosures of specified transactions included in the measurement of normalised profit from operations, in compliance with IFRS 8.23. As a result, Discovery has implemented the following changes: ■ To reflect material items of income and expense, marketing and administration expenses have been disaggregated to separately present staff costs, which represent a material component of these expenses. The staff costs shown in the segment are net of allocations to the insurance service expense. A separate note (A.1.2) has been included in the segment information for this disclosure. ■ Discovery has included a separate note (A.1.1) to clearly present items of revenue and other income arising from internal transactions with other segments. To implement the changes as disclosed in note A.1.1. for internal transactions, Discovery has revised the presentation of intersegment charges, recoveries, revenues, and income: ■ Prior to 1 July 2024 – Intercompany recoveries, recharges, other income, and intercompany revenues were offset within marketing and administration expenses, with the net expense reflected in the segment. ■ Effective from 1 July 2024 – The presentation of these items within segment information now aligns more closely with the financial statements of the respective business lines. ■ These changes have been enabled through the new financial reporting system and required significant development to ensure the accuracy of the information. As permitted by IFRS 8.29, prior-year segment information has not been restated due to the cost and effort required to reperform the changes for the prior period. Refer to Note A.1.1 for further details, ensuring that the results for the year ended 30 June 2025 are comparable to those for the year ended 30 June 2024. 2. Prior to 1 July 2024, VCSL was included as part of the UK Health segment alongside Vitality Health. Effective from 1 July 2024 (with restatement of comparative information), VCSL, as the central services company within the UK, has been excluded from the UK Health segment and instead included in All other segments. This treatment aligns VCSL with the treatment of Discovery Central Services. This change, together with the other changes noted earlier, had no impact on the normalised profit from operations for the UK Health segment 3. The CODM has revised their view of SA Bank costs related to health and lifestyle benefits to align more closely with the treatment in Discovery Bank’s separate statutory accounts. These costs were previously disclosed within marketing and administration expenses and are now included within the Net banking fee and commission income of SA Bank. The comparative information has been restated accordingly to reflect this revised treatment resulting in a decrease of R328 million in the Net banking and commission income, with an equal and opposite decrease in marketing and administration expenses. This change in management view had no resultant change in the Group income statement. 4. Prior to 1 July 2024, the Group Risk portfolio of the CEB business was included within the SA Life segment, while the remainder of the CEB business was reported under All other segments in the segment information. To reflect the operational and managerial alignment of CEB with SA Life’s business activities and internal reporting structure, the remainder of CEB business was reclassified to the SA Life segment effective from 1 July 2024.The comparative information has been restated accordingly, resulting in a R67 million decrease in SA Life’s normalised profit from operations, with a corresponding increase in All other segments. The change has no impact on the Group’s normalised profit from operations. 5. Prior to 1 July 2024, Vitality Drive International (VDI) was included under All other segments. Effective from 1 July 2024 (with no restatement of comparative information), VDI has been reclassified to the SA Insure segment. This reflects the strategic integration of VDI within Discovery Insure’s international expansion and incentive-based behaviour programme, aligning the reporting structure with operational responsibility and performance oversight. Discovery Insure’s previously published normalised profit from operations has not been restated as the effect was immaterial in the prior period 6. From 1 July 2024, SA Invest amended the presentation of specified income tax expenses within its business line to improve the usefulness of the information provided and to enhance comparability with peers in the market. Within its normalised profit from operations, SA Invest now includes tax expenses specific to policyholder tax funds that are directly chargeable to, or recoverable from, policyholders. These are also often referred to as ‘policyholder taxes’ or ‘contract holder taxes’. The comparative information has been restated to reflect this revised presentation. A. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS continued 19 -- 21 of 96 -- A.1 SEGMENT INFORMATION continued R million Notes SA Health SA Life 30 June 2025 Income statement Insurance revenue 518 19 149 – Contracts measured under the General measurement model/Variable fee approach – 15 419 – Contracts measured under Premium allocation approach – 518 3 730 Insurance service expenses (362) (15 512) – Claims and benefits (216) (11 375) – Insurance service expense and other (66) (1 795) – Insurance acquisition cash flows (80) (2 342) Tax specific to policyholder tax funds1 – – Insurance service result (pre-reinsurance) 156 3 637 Net expenses from reinsurance contracts (1) (1 021) – Reinsurance expense (2) (3 838) – Insurance claims recovered from reinsurers 1 2 817 Insurance service result 155 2 616 Net financial result from insurance finance income and expense – 2 466 – Net finance income/(expense) from insurance contracts – 2 590 – Net finance expense from reinsurance contracts – (124) Investment income using the effective interest rate method 11 15 Net fair value gains on financial instruments at fair value through profit or loss 29 3 537 Fair value adjustments to liabilities under investment contracts2 – (2 961) Third-party interest: fair value adjustments to liabilities under investment contracts – – Intersegment funding – 362 Other losses on financial instruments – – Net insurance and investment results 195 6 035 Fee income from administration businesses A.1.1 9 766 188 Vitality income – – Net banking fee and commission income – – – Banking fee and commission income – – – Banking fee and commission expense – – Net banking interest and similar income – – – Banking interest and similar income using the effective interest rate – – – Banking interest and similar expense using the effective interest rate – – Other income A.1.1 1 838 119 Non-insurance revenue and income 11 604 307 Net income 11 799 6 342 Non-insurance acquisition costs – – Expected credit losses – – Marketing and administration expenses A.1.2 (7 540) (817) Share of net profits from equity-accounted investments – – Normalised profit/(loss) from operations A.2 4 259 5 525 Investment income earned on shareholder investments and cash 98 31 Intercompany investment income – – Net fair value gain on financial assets at fair value through profit or loss – 51 Loss from dilution of equity accounted investments – – Impairment of goodwill (20) – Amortisation of intangibles from business combinations – – Market rentals related to Head Office building adjusted for finance costs and depreciation – – Restructuring costs – – Interest expenses on borrowings and lease liabilities (2) (1) Intercompany finance expenses on borrowings (447) – Foreign exchange (losses)/gains (5) (14) Profit/(loss) before income tax 3 883 5 592 Income tax expense (1 046) (1 508) Profit/(loss) for the year 2 837 4 084 Profit attributable to: – Ordinary shareholders 2 843 4 084 – Preference shareholders – – – Non-controlling interest (6) – 1 Tax specific to policyholder tax funds is reallocated from the income tax expense line. This includes taxes that are directly chargeable to the policyholder under insurance contracts, with a corresponding change in the policyholder fund values, which are included within the insurance revenue line. 2 The value is reflected net of contract holder taxes, which are taxes directly chargeable to the contract holder. There is a corresponding change in the contract holder value, which is included in the fair value measurement. A. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS continued 20 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 22 of 96 -- SA Invest SA Insure SA Bank UK Health UK Life All other segments Segment total IFRS reporting adjustments IFRS total 4 560 6 217 – 19 124 8 050 95 57 713 – 57 713 4 560 – – – 8 050 – 28 029 – 28 029 – 6 217 – 19 124 – 95 29 684 – 29 684 (2 676) (5 499) – (17 292) (7 595) (92) (49 028) – (49 028) (608) (3 000) – (11 300) (3 681) (51) (30 231) – (30 231) (1 057) (1 597) – (3 981) (879) (37) (9 412) – (9 412) (1 011) (902) – (2 011) (3 035) (4) (9 385) – (9 385) (97) – – – – – (97) 97 – 1 787 718 – 1 832 455 3 8 588 97 8 685 – (112) – (3) (165) (4) (1 306) – (1 306) – (130) – (5) (8 839) (34) (12 848) – (12 848) – 18 – 2 8 674 30 11 542 – 11 542 1 787 606 – 1 829 290 (1) 7 282 97 7 379 (15 831) (20) – – 417 – (12 968) (120) (13 088) (15 831) (20) – – 716 – (12 545) (120) (12 665) – – – – (299) – (423) – (423) 75 268 – 179 81 17 646 352 998 17 058 11 52 70 – – 20 757 5 061 25 818 (905) – – – – – (3 866) 56 (3 810) – – – – – – – (4 394) (4 394) (362) – – – – – – – – – – (9) – – – (9) – (9) 1 822 865 43 2 078 788 16 11 842 1 052 12 894 1 260 – – 35 – 3 185 14 434 (108) 14 326 – – – 31 267 5 575 5 873 (551) 5 322 – – 1 373 – – (77) 1 296 399 1 695 – – 2 238 – – – 2 238 – 2 238 – – (865) – – (77) (942) 399 (543) – – 965 – – – 965 1 966 – – 2 203 – – – 2 203 – 2 203 – – (1 238) – – – (1 238) 1 (1 237) 1 79 69 19 – 14 591 16 716 (14 884) 1 832 1 261 79 2 407 85 267 23 274 39 284 (15 143) 24 141 3 083 944 2 450 2 163 1 055 23 290 51 126 (14 091) 37 035 (395) – – – – (294) (689) 305 (384) – – (279) – – – (279) – (279) (701) (213) (2 239) (975) (424) (23 305) (36 214) 14 449 (21 765) – 86 – – 6 1 174 1 266 (51) 1 215 1 987 817 (68) 1 188 637 865 15 210 612 15 822 13 7 – – – 203 352 (352) – – – – – – 1 351 1 351 (1 351) – 54 – – – – – 105 (105) – – (32) – – – – (32) – (32) – – – – – – (20) – (20) – (51) – – – (71) (122) 122 – – – – – – (72) (72) 72 – – – – – – (80) (80) 80 – – – – (18) (201) (1 588) (1 810) (277) (2 087) – – – – (444) (460) (1 351) 1 351 – (5) – – – 1 (13) (36) – (36) 2 049 741 (68) 1 170 (7) 135 13 495 152 13 647 (793) (216) 25 (311) (62) (26) (3 937) (152) (4 089) 1 256 525 (43) 859 (69) 109 9 558 – 9 558 1 256 525 (43) 859 (69) 16 9 471 – 9 471 – – – – – 93 93 – 93 – – – – – – (6) – (6) 21 -- 23 of 96 -- A.1 SEGMENT INFORMATION continued R million Notes SA Health SA Life 30 June 2024 Restated1 Income statement Insurance revenue 435 17 522 – Contracts measured under the General measurement model/Variable fee approach – 14 014 – Contracts measured under Premium allocation approach 435 3 508 Insurance service expenses (341) (15 207) – Claims and benefits (224) (12 104) – Insurance service expense and other (54) (1 096) – Insurance acquisition cash flows (63) (2 007) Tax specific to policyholder tax funds2 Insurance service result (pre-reinsurance) 94 2 315 Net expenses from reinsurance contracts (1) (458) – Reinsurance expense (1) (3 692) – Insurance claims recovered from reinsurers – 3 234 Insurance service result 93 1 857 Net financial result from insurance finance income and expense – 2 626 – Net finance income/(expense) from insurance contracts – 2 821 – Net finance expense from reinsurance contracts – (195) Investment income using the effective interest rate method – 32 Net fair value (losses)/gains on financial instruments at fair value through profit or loss (6) 2 420 Fair value adjustments to liabilities under investment contracts3 – (1 450) Third-party interest: fair value adjustments to liabilities under investment contracts – – Intersegment funding (13) (282) Other gains on financial instruments – – Net insurance and investment results 74 5 203 Fee income from administration businesses A.1.1 9 233 155 Vitality income A.1.1 – – Net banking fee and commission income – – – Banking fee and commission income – – – Banking fee and commission expense – – Net banking interest and similar income – – – Banking interest and similar income using the effective interest rate – – – Banking interest and similar expense using the effective interest rate – – Other income A.1.1 1 173 3 Non-insurance revenue and income 10 406 158 Net income 10 480 5 361 Non-insurance acquisition costs – – Expected credit losses – – Marketing and administration expenses A.1.2 (6 508) (523) Share of net profits from equity-accounted investments – – Normalised profit/(loss) from operations A.2 3 972 4 838 Investment income earned on shareholder investments and cash 120 27 Intercompany investment income – – Net fair value gains/(losses) on financial assets at fair value through profit or loss – 87 Gain/(loss) from dilution and disposal of equity accounted investments – – Amortisation of intangibles from business combinations – – Market rentals related to Head Office building adjusted for finance costs and depreciation – – Restructuring costs – – Interest expenses on borrowings and lease liabilities (2) (1) Intercompany finance expenses on borrowings (412) – Foreign exchange gains/(losses) (6) (11) Profit/(loss) before income tax 3 672 4 940 Income tax expense (987) (1 334) Profit/(loss) for the year 2 685 3 606 Profit attributable to: – Ordinary shareholders 2 695 3 606 – Preference shareholders – – – Non-controlling interest (10) – 1 The comparative information has been restated due to (1) correction of a prior period error as discussed in section D1.1 as well as (2) those changes noted in items 2,3,4 and 6 as discussed in the introduction to Segment information “Changes from 1 July 2024”. 2 Tax specific to policyholder tax funds is reallocated from the income tax expense line. This includes taxes that are directly chargeable to the policyholder under insurance contracts, with a corresponding change in the policyholder fund values, which are included within the insurance revenue line. 3 The value is reflected net of contract holder taxes, which are taxes directly chargeable to the contract holder. There is a corresponding change in the contract holder value, which is included in the fair value measurement. A. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS continued 22 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 24 of 96 -- SA Invest SA Insure SA Bank UK Health UK Life All other segments Segment total IFRS reporting adjustments IFRS total 4 360 5 737 – 16 474 6 904 698 52 130 – 52 130 4 360 – – – 6 904 – 25 278 – 25 278 – 5 737 – 16 474 – 698 26 852 – 26 852 (2 671) (5 471) – (15 456) (6 217) (754) (46 117) – (46 117) (462) (3 540) – (9 562) (3 098) (472) (29 462) – (29 462) (1 148) (1 069) – (4 127) (509) (135) (8 138) – (8 138) (1 061) (862) – (1 767) (2 610) (147) (8 517) – (8 517) (85) (85) 85 – – 1 604 266 – 1 018 687 (56) 5 928 85 6 013 – (24) – (8) (408) (16) (915) – (915) – (474) – (8) (5 738) (275) (10 188) – (10 188) – 450 – – 5 330 259 9 273 – 9 273 1 604 242 – 1 010 279 (72) 5 013 85 5 098 (9 850) – – – 231 – (6 993) (300) (7 293) (9 850) – – – 379 – (6 650) (300) (6 950) – – – – (148) – (343) – (343) 49 209 – 175 65 12 542 318 860 10 098 1 1 60 – (48) 12 526 3 719 16 245 (749) – – – – 46 (2 153) 11 (2 142) – – – – – – – (2 873) (2 873) 282 13 – – – – – – – – – 5 – – – 5 – 5 1 434 465 6 1 245 575 (62) 8 940 960 9 900 1 215 – – 31 – 2 962 13 596 – 13 596 – – – 23 264 4 368 4 655 – 4 655 – – 1 039 – – 31 1 070 328 1 398 – – 1 795 – – – 1 795 77 1 872 – – (756) – – 31 (725) 251 (474) – – 779 – – – 779 – 779 – – 1 840 – – – 1 840 – 1 840 – – (1 061) – – – (1 061) – (1 061) – 16 – 22 – 106 1 320 60 1 380 1 215 16 1 818 76 264 7 467 21 420 388 21 808 2 649 481 1 824 1 321 839 7 405 30 360 1 348 31 708 (383) – – – – (108) (491) – (491) – – (183) – – – (183) – (183) (727) (282) (2 095) (886) (470) (7 459) (18 950) (694) (19 644) – 49 – – 6 970 1 025 (50) 975 1 539 248 (454) 435 375 808 11 761 604 12 365 16 – – – – 155 318 (318) – – – – – – 1 046 1 046 (1 046) – 75 – – – – – 162 (162) – – 22 – – – – 22 – 22 – (49) – – – (56) (105) 105 – – – – – – (105) (105) 105 – – – – – – (48) (48) 48 – – – – (17) (217) (1 513) (1 750) (286) (2 036) – – – – (464) (170) (1 046) 1 046 – (20) – – – – (50) (87) – (87) 1 610 221 (454) 418 (306) 67 10 168 96 10 264 (273) (58) 171 (29) 25 (134) (2 619) (96) (2 715) 1 337 163 (283) 389 (281) (67) 7 549 – 7 549 1 337 163 (283) 389 (281) (158) 7 468 – 7 468 – – – – – 91 91 – 91 – – – – – – (10) – (10) 23 -- 25 of 96 -- A.1 SEGMENT INFORMATION continued A.1.1 Revenues and income with other operating segments The net income presented within each respective segment includes the following items of revenue and income derived from transactions with other operating segments of the Group: R million SA Health SA Life 30 June 2025 Fee income from administration businesses – – Vitality income – – Other income 235 130 Total 235 130 A.1.2 Material items of expenses Additional information on material items of expenses included within the marketing and administration expenses: R million SA Health SA Life 30 June 2025 Depreciation and amortisation (174) (1) Derecognition of intangible assets and property and equipment – (43) Impairment of intangible assets and property and equipment (20) (28) Staff costs (3 038) (284) Other expenses1 (4 308) (461) Total: Marketing and administration expenses (7 540) (817) 30 June 2024 Depreciation and amortisation (171) – Derecognition of intangible assets and property and equipment – – Impairment of intangible assets and property and equipment – – Staff costs (2 625) (212) Other expenses1 (3 712) (311) Total: Marketing and administration expenses (6 508) (523) 1 Included in SA Health other expenses are IT systems and consumables of R1 576 million (2024: R1 488 million). Changes since 1 July 2024: As noted earlier, Discovery changed the presentation of intercompany recoveries, recharges, other income and intercompany revenues. If the information for the year ended 30 June 2025 was presented on a similar basis to the results for the year ended 30 June 2024, the ‘Total: Marketing and administration expenses’ would have been reduced by the value equal to the ‘Total’ as disclosed in Note A.1.1. A. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS continued 24 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 26 of 96 -- SA Invest SA Insure SA Bank UK Health UK Life All other segments Segment total – – – – – 94 94 – – – – – 551 551 1 64 69 94 – 14 784 15 377 1 64 69 94 – 15 429 16 022 SA Invest SA Insure SA Bank UK Health UK Life All other segments Segment total (24) (1) (368) – (58) (1 273) (1 899) – (52) – – (1) (45) (141) – (18) – (79) – – (145) (262) (95) (984) – – (8 062) (12 725) (415) (47) (887) (896) (365) (13 925) (21 304) (701) (213) (2 239) (975) (424) (23 305) (36 214) (17) (43) (339) (5) (49) (1 276) (1 900) – (16) – – – (39) (55) – – – (13) – (9) (22) (210) (71) (911) – – (7 486) (11 515) (500) (152) (845) (868) (421) 1 351 (5 458) (727) (282) (2 095) (886) (470) (7 459) (18 950) 25 -- 27 of 96 -- A.2 NORMALISED PROFIT FROM OPERATIONS The following table shows the main components of the normalised profit from operations for the year ended 30 June 2025: R million Group 2025 Restated Group 20241 % Change Discovery Health 4 259 3 972 7% Discovery Life 5 525 4 838 14% Discovery Invest 1 987 1 539 29% Discovery Insure – Personal lines 817 248 229% Discovery Bank (68) (454) (85%) Other initiatives and central costs* (515) (269) 91% Normalised profit from Discovery SA 12 005 9 874 22% VitalityHealth 1 188 435 173% VitalityLife 637 375 70% Closure costs of VitalityInvest* – (75) (100%) Vitality Health International – Ping An Health Insurance* 1 206 1 124 7% Vitality Health International – Other* (291) (386) (25%) Vitality Network* 554 533 4% Other initiatives and central costs* (89) (119) (25%) Normalised profit from Vitality 3 205 1 887 70% Normalised profit from operations 15 210 11 761 29% 1 The comparative information has been restated due to correction of a prior period error. Refer to section D1.1 for more detail. * Presented in ‘All other segments’ on the Segment information disclosure note in section A.1. A.3 EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS Group 2025 Restated Group 20241 Number of shares used in calculation Weighted number of shares in issue ('000) 665 168 661 071 Diluted weighted number of shares ('000) 668 715 665 016 Earnings per share (cents): – basic 1 402.2 1 110.3 – diluted 1 394.9 1 103.7 Headline earnings per share (cents): – basic 1 447.0 1 117.0 – diluted 1 439.4 1 110.4 Normalised headline earnings per share (cents): – basic 1 470.4 1 136.2 – diluted 1 462.8 1 129.5 WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES (‘000) Issued ordinary shares at 1 July 661 021 658 424 Effect of share options exercised and vesting of share awards 4 147 2 647 Weighted-average number of ordinary shares at 30 June (basic) 665 168 661 071 Effect of share options exercised and vesting of share awards 3 547 3 945 Weighted-average number of ordinary shares at 30 June (diluted) 668 715 665 016 EARNINGS RECONCILIATION (R MILLION) Profit attributable to the ordinary shareholders 9 471 7 468 Adjusted for: – Profit attributable to non-forfeitable dividend share plan (144) (128) Basic earnings attributable to the ordinary shareholders 9 327 7 340 1 The comparative information has been restated due to correction of a prior period error. Refer to section D1.1 for more detail. A. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS continued 26 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 28 of 96 -- A.3 EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS continued HEADLINE EARNINGS RECONCILIATION Headline earnings per share is disclosed per the JSE Listings Requirements and is calculated in accordance with the circular titled Headline Earnings issued by SAICA, as amended from time to time. Headline earnings per share is based on the net profit after tax attributable to ordinary shareholders adjusted for items of a capital nature and the weighted average number of ordinary shares in issue. R million Group 2025 Restated Group 20241 Gross Tax Net Gross Tax Net Basic earnings attributable to the ordinary shareholders 9 327 7 340 Adjusted for: IFRS 3: Goodwill impairment 20 – 20 – – – IFRS 5: Impairment - NCAHFS 79 – 79 – – – IAS 16: Gain on disposal of property and equipment (1) – (1) (1) – (1) IAS 16: Loss on derecognition of property and equipment 11 (3) 8 10 (3) 7 IAS 16: Impairment of property and equipment – – – 14 – 14 IAS 38: Loss on derecognition of intangible assets 131 (19) 112 45 (10) 35 IAS 38: Impairment of intangibles 65 (10) 55 8 (2) 6 IAS 28: Loss/(gain) on the dilution and disposal of equity-accounted investments 32 (7) 25 (22) 5 (17) Headline earnings (basic and diluted) 9 625 7 384 1 The comparative information has been restated due to correction of a prior period error. Refer to section D1.1 for more detail. NORMALISED HEADLINE EARNINGS RECONCILIATION Normalised headline earnings is calculated per Discovery’s policy as set out in the Accounting Policies in note E.2. Management considers that normalised headline earnings is an appropriate alternative performance measure to enhance the comparability and understanding of the financial performance of the Group. R million Group 2025 Restated Group 20241 Gross Tax Net Gross Tax Net Headline earnings 9 625 7 384 Adjusted for: – Gain arising from the recognition of deferred tax asset resulting from assessed loss: Initial recognition – (9) (9) – – – – Amortisation of intangible assets arising from business combinations 71 (18) 53 56 (15) 41 – Restructuring costs 80 (19) 61 48 (11) 37 Adjustments attributable to equity-accounted investments: – – – Amortisation of intangible assets arising from business combinations 51 – 51 49 – 49 Normalised headline earnings (basic and diluted) 9 781 7 511 1 The comparative information has been restated due to correction of a prior period error. Refer to section D1.1 for more detail. A. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS continued 27 -- 29 of 96 -- A.4 REVENUE FROM NON-INSURANCE ACTIVITIES Discovery Group’s Revenue includes ‘Fee income from administration businesses’, ‘Vitality income’ and ‘Banking fee and commission income’. The split of revenue per geographical region and reportable segment can be viewed in Note A.1 Segment information. The split of revenue according to the timing of satisfaction of performance obligations, i.e. ‘over time’ or a ‘point-in-time’ is as follows: R million Group 2025 Group 2024 Fee income from administration businesses 14 326 13 596 – Over time 13 769 13 573 – Point-in-time 557 23 Vitality income 5 322 4 655 – Over time 3 671 3 178 – Point-in-time 1 651 1 477 Banking fee and commission income 2 238 1 872 – Over time 1 455 836 – Point-in-time 783 1 036 A.5 BORROWINGS AT AMORTISED COST R million Reference Group 2025 Group 2024 Borrowings from banks and listed debt 16 103 17 511 – UK borrowings A.5.1 3 710 3 549 – South African borrowings A.5.2 12 393 13 962 Bank overdraft in underlying liabilities of consolidated Unit Trusts 2 6 Lease liabilities 3 941 4 145 – 1 Discovery Place (1 DP) 3 124 3 246 – Other lease liabilities 817 899 20 046 21 662 A.5.1 UK borrowing facilities Carrying amount Facility amount GBP million Capital repayment and maturity date2 Group 2025 Group 2024 Variable rate GBP R GBP R 25 SONIA + 275bps1 At maturity – 23 December 2025 25 608 25 589 75 SONIA + 300bps1 At maturity – 21 December 2025 75 1 828 74 1 714 55 SONIA + 285bps1 At maturity – 12 December 2025 52 1 274 54 1 246 152 3 710 153 3 549 1 Interest payable quarterly in arrears. 2 In preparation for the upcoming debt maturities in the latter part of 2025, Discovery initiated a restructuring of its funding arrangements to optimise financing costs. As part of this process, in August 2025 Discovery successfully secured a R2.1 billion revolving credit facility, priced at 3-month JIBAR plus 115 basis points. Total finance costs in respect of the UK borrowings for the year ended 30 June 2025 was £12.14 million (R285 million) (2024: £13 million (R306 million)). A.5.2 South African borrowings CREDIT RATING In November 2024 Moody’s Investors Service (“Moody’s”) reaffirmed Discovery Limited’s global-scale long-term issuer rating of Ba3 and upgraded the national-scale long-term issuer rating to Aa3.za from A1.za. The outlook remained unchanged as stable, aligned to the outlook of the country. A. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS continued 28 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 30 of 96 -- A.5 BORROWINGS AT AMORTISED COST continued A.5.2 South African borrowings continued DISCOVERY LIMITED Discovery had R2.2 billion in Domestic Medium Term Notes (DMTN) maturing in November 2024. As a risk mitigation measure, it raised R1.5 billion notes in May 2024 and to complete the refinancing of the maturing November 2024 notes and avail itself of continued favourable debt markets, the Company raised a further R1.75 billion in November 2024. To facilitate these issuances, in advance of settling the maturing notes, Discovery increased the size of its notes programme registered in 2017 to R12.5 billion from R10 billion on the same terms and conditions. The excess proceeds were used to settle R1.1 billion in notes maturing in February 2025, with the remaining R1.4 billion maturity being extended to 21 May 2025. An additional R1.515 billion notes were issued on 21 May 2025 to apply towards those notes maturing. Carrying value R million Facility amount R million Variable rate Interest per annum Capital repayment and maturity date Group 2025 Group 2024 Listed DMTN 200 – 10.46%1 At maturity – 21 November 2024 – 202 800 3-month JIBAR + 191bps 8.40%2,3 At maturity – 21 November 2024 – 809 1 200 3-month JIBAR + 191bps 7.30%2,3 At maturity – 21 November 2024 – 1 215 700 3-month JIBAR + 180bps 8.49%2,3 At maturity – 21 August 2026 707 707 300 3-month JIBAR + 180bps 7.60%2,3 At maturity – 21 August 2026 303 304 792 3-month JIBAR + 173bps 7.98%2,3 At maturity – 21 May 2027 799 800 226 3-month JIBAR + 180bps 7.98%2,3 At maturity – 21 May 2029 228 228 576 3-month JIBAR + 140bps 7.50%2,3 At maturity – 21 November 2027 581 582 924 3-month JIBAR + 159bps 8.17 2,3 At maturity – 21 November 2029 932 935 404 – 7.90%1 At maturity – 21 November 2025 392 – 750 3-month JIBAR + 140bps 7.19%2,3 At maturity – 21 November 2027 758 – 1 000 3-month JIBAR + 159bps 8.17% 2,3 At maturity – 21 November 2029 1 012 – 1 111 3-month JIBAR + 95bps 7.46% 3 At maturity – 21 May 2026 1 120 – Unlisted DMTN4 2 500 – 9.62%3 At maturity – 22 February 2025 – 2 525 1 650 – 9.55%3 At maturity – 10 March 2026 1 659 1 659 Other 1 000 3-month JIBAR + 190bps 8.38%2,3 At maturity – 2 March 2028 1 000 999 500 3-month JIBAR + 190bps 7.51%2,3 At maturity – 2 March 2028 500 499 Total Discovery Limited Borrowings 9 991 11 464 1 Interest is payable semi-annually in arrears. 2 The interest rate has been fixed through interest rate swaps. 3 Interest payable quarterly in arrears. 4 During the financial year ended 30 June 2020, Discovery Limited refinanced R3.6 billion bank-syndicated loans through the issue of unlisted DMTN notes. The notes, although underwritten by a bank until maturity, are structured to enable short-term issuances into the commercial paper market on an ongoing basis. DISCOVERY CENTRAL SERVICES Carrying value R million Facility amount R million Interest rate per annum Capital repayment and maturity date Group 2025 Group 2024 1 400 9.97%1 At maturity – 20 December 2028 1 408 1 407 650 11.56% At maturity – 29 October 2027 300 396 691 3-month JIBAR + 190bps1,3 At maturity – 30 June 2027 694 695 1 500 3-month JIBAR + 145bps1,4 At maturity – 08 June 2026 – – 500 Prime rate less 145bps5 At maturity – 364-day notice – – Total Discovery Central Services Borrowings 2 402 2 498 1 Interest payable quarterly in arrears. 2 Instalments of interest and capital are monthly. 3 The interest rate exposure has been capped at 8.36% through a derivative instrument. 4 During the current period, the maturity date of this Revolving Credit Facility has been extended to 08 June 2026. This facility was not drawn down. 5 The Revolving Credit Facility is a committed 364-day notice facility granted in November 2023. A commitment fee of 0.60% per annum is paid monthly in arrears on the undrawn portion. This facility was reduced from R750 million to R500 million during the period and was not drawn down. Total finance costs in respect of South African borrowings and related hedges for the year ended 30 June 2025 was R1 261 million (2024: R1 226 million). A. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS continued 29 -- 31 of 96 -- A.6 FAIR VALUE HIERARCHY The Group’s assets and liabilities measured at fair value are disclosed in accordance with the fair value hierarchy. The hierarchy has three levels that reflect the significance of the inputs used in measuring fair value.These are as follows: Level 1: includes those assets and liabilities that are measured using unadjusted, quoted prices in an active market for identical financial instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm’s length basis. Level 2: includes those assets and liabilities that are valued using techniques based significantly on observable market data. Assets and liabilities in this category are valued using: (a) Quoted prices for similar instruments or identical instruments in markets that are not considered to be active; or (b) Valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on observable market data. Level 3: includes those assets and liabilities that are valued using valuation techniques that incorporate information other than observable market data and where at least one input (which could have a significant effect on the instruments’ valuation) cannot be based on observable market data. R million Level 1 Level 2 Level 3 Total 30 June 2025 Financial assets Financial instruments mandatorily at fair value through profit or loss: 141 140 52 636 – 193 776 – Equity portfolios 87 458 12 477 – 99 935 – Debt portfolios 53 682 2 186 – 55 868 – Money market portfolios – 12 948 – 12 948 – Multi-asset portfolios – 25 025 – 25 025 Financial instruments at fair value through other comprehensive income: – – 14 14 – Equity portfolios – – 14 14 Derivative financial instruments at fair value: – 41 22 63 – used as cash flow hedges – 1 – 1 – not designated as hedging instruments – 40 22 62 Total financial assets 141 140 52 677 36 193 853 Non-financial assets Non-current asset held for sale1 – – 62 62 Total assets 141 140 52 677 98 193 915 Financial liabilities Third-party interest in consolidated funds – 35 932 – 35 932 Investment contracts at fair value through profit or loss – 32 188 – 32 188 Derivative financial instruments at fair value: – 135 – 135 – used as cash flow hedges – 117 – 117 – not designated as hedging instruments – 18 – 18 Total financial liabilities – 68 255 – 68 255 1 The fair value was determined from an agreed sales price between unrelated parties, reflecting an arm’s length transaction under current market conditions. Given the agreed sales price, no variability is expected in the fair value measurement, as the transaction price represents the best available estimate of fair value. The measurement approach incorporates relevant observable market inputs where available. The Stockport non-current asset held for sale has been sold in July 2025. There were no transfers between hierarchy levels during the current financial period. A. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS continued 30 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 32 of 96 -- A.6 FAIR VALUE HIERARCHY continued R million Level 1 Level 2 Level 3 Total 30 June 2024 Financial assets Financial instruments mandatorily at fair value through profit or loss: 97 618 68 037 16 165 672 – Equity portfolios 52 145 8 089 16 60 251 – Debt portfolios 45 473 1 626 – 47 099 – Money market portfolios – 15 786 – 15 786 – Multi-asset portfolios – 42 536 – 42 536 Derivative financial instruments at fair value: – 43 – 43 – used as cash flow hedges – 14 – 14 – not designated as hedging instruments – 29 – 29 Total financial assets 97 618 68 081 16 165 715 Non-financial assets Non-current asset held for sale1 – – 136 136 Total assets 97 618 68 081 152 165 851 Financial liabilities Third-party interest in consolidated funds – 31 456 – 31 456 Investment contracts at fair value through profit or loss – 25 710 – 25 710 Derivative financial instruments at fair value: – 31 – 31 – used as cash flow hedges – 24 – 24 – not designated as hedging instruments – 7 – 7 Total financial liabilities – 57 197 – 57 197 1 The fair value was determined from an agreed sales price between unrelated parties, reflecting an arm’s length transaction under current market conditions. Given the agreed sales price, no variability is expected in the fair value measurement, as the transaction price represents the best available estimate of fair value. The measurement approach incorporates relevant observable market inputs where available. A. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS continued 31 -- 33 of 96 -- A.6 FAIR VALUE HIERARCHY continued Specific valuation techniques used to value financial instruments in level 2 and level 3 If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange-traded financial instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques including the use of recent arm’s-length market transactions, reference to the current fair value of another instrument that is substantially the same, discounted cash flow techniques, option pricing models or other valuation techniques that provide a reliable estimate of prices obtained in actual market transactions. Valuation techniques used in determining the fair value of assets and liabilities: Instruments Valuation technique Main inputs and assumptions for level 2 and level 3 fair value hierarchy items Within equity portfolios, Equity- linked notes The calculation of the daily value of the equity-linked investments is made by the provider of the note. Discovery has procedures in place to ensure that these prices are correct. Aside from the daily reasonableness checks versus similar funds and movement since the prior day’s price, the fund values are calculated with reference to a specific formula or index, disclosed to the policyholders, which is recalculated by Discovery in order to check if the price provided by the provider is correct. ■ discount rate ■ spot price of the underlying Debt portfolios and Money market instruments Money market instruments are valued by discounting the future cash flows using a risk-adjusted discount rate. ■ discount rate, credit spread Multi-assets The fair values of financial liabilities arising on the consolidation of mutual funds are determined using the quoted put (exit) price provided by the fund manager and discounted for the applicable notice period. The fair value of a financial liability with a demand feature is not less than the amount payable on demand, discounted from the first date on which the amount could be required to be paid. ■ discount rate Investment contracts at fair value, including third-party interest in consolidated funds Unit-linked policies: assets that are linked to the investment contract liabilities are accounted for by the Group. The investment contract obliges the Group to use these assets to settle these liabilities. Therefore, the fair value of third-party interest in consolidated funds and investment contract liabilities is determined with reference to the fair value of the underlying assets (i.e., amount payable on surrender of the policies). Annuity: certain discounted cash flow models are used to determine the fair value of the stream of future payments. ■ discount rate ■ spot price of the underlying Derivatives Standard derivative contracts are valued using market-accepted models and quoted parameter inputs. More complex derivative contracts are modelled using more sophisticated modelling techniques applicable to the instrument. Techniques include: ■ Discounted cash flow model ■ Black-Scholes model ■ Combination technique models ■ discount rate ■ spot price of the underlying ■ correlation factors ■ volatilities ■ earnings yield ■ valuation multiples Unlisted equity instruments at fair value For unlisted equity instruments, a discounted cash flow methodology is used. The discounted cash flow methodology values an asset by determining the present value of its expected future net cash flows. This valuation considers both historic experience and future projected budgets. The valuation is stress tested by considering earnings multiples, e.g., price-earnings multiple (P/E ratio). ■ discount rate ■ growth rate ■ projected earnings ■ valuation multiples, e.g., P/E ratio A. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS continued 32 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 34 of 96 -- SECTION B OTHER SIGNIFICANT ITEMS IN THESE RESULTS 34 B.1 Exchange rates to the South African Rand used in the preparation of these results 34 B.2 Capital management, financial leverage ratio and covenants 36 B.3 Impact of financial risk variances within the SA Life and UK Life operating segment 36 B.4 Cash and cash equivalents 37 B.5 Consolidation of Discovery Unit Trusts 38 B.6 Material transactions with related parties 38 B.7 Major customers and other Discovery entities not part of Discovery Group 38 B.8 Changes in directorate 38 B.9 Events after reporting date and dividend declaration in respect of the year ended 30 June 2025 33 -- 35 of 96 -- B.1 EXCHANGE RATES TO THE SOUTH AFRICAN RAND USED IN THE PREPARATION OF THESE RESULTS Closing rates Average rates Exchange rate to SA rand Group 2025 Group 2024 Group 2025 Group 2024 US dollar 17.77 18.26 18.16 18.71 Pound sterling 24.34 23.07 23.48 23.55 Chinese Yuan 2.48 2.51 2.51 2.59 B.2 CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS The Group’s capital is defined as capital and reserves attributable to shareholders, as presented in the Group statement of financial position. The Group’s objectives when managing capital are: ■ To comply with the statutory capital and liquidity requirements in each of its regulated entities; ■ To maintain a capital and liquidity buffer in excess of the statutory requirements in order to reduce the risk of breaching the statutory requirements; ■ To ensure that sufficient capital is available to fund the Group’s working capital and strategic capital requirements; ■ To achieve an optimal and efficient capital funding profile; and ■ To consider capital management needs both in the short term and over a five-year planning horizon. Discovery has a Finance and Capital Committee that ensures alignment in strategic financial management between the centre and subsidiaries within South Africa, UK and US. The committee is the governance body for all capital allocation activities across the Group ultimately overseen by the Board. A range of capital-raising options are available to manage the capital structure of the Group, which includes the issue of new shares, debt, financial reinsurance arrangements and other hybrid instruments. Regulatory capital For Group subsidiaries that operate in the insurance and financial services sectors, the relevant regulator specifies the minimum amount and type of capital that must be held by each of the subsidiaries in addition to their insurance liabilities. The minimum required capital must be maintained at all times throughout the period. Discovery Life and Discovery Insure are regulated under the Insurance Act 18 of 2017 (Insurance Act), and the related Prudential Standards, while VitalityHealth and VitalityLife are regulated under the European Solvency II regulatory regime. The table below summarises the capital requirements of insurance companies on a statutory basis, across the Group subsidiaries, and the actual solvency capital held in relation to these requirements as at the end of the reporting period. June 2025 June 2024 Statutory capital requirements Cover Statutory capital requirements Cover Discovery Life R23 479 million 1.9 times R22 365 million 1.8 times Discovery Insure R1 112 million 2.1 times R1 222 million 1.6 times VitalityHealth £126 million 1.8 times £116 million 1.6 times (R3 072 million) (R2 670 million) VitalityLife £383 million 2.0 times £350 million 2.0 times (R9 322 million) (R8 070 million) Discovery Bank’s common equity tier 1 (CET1) ratio is 16.31% (2024: 17.63%). In addition, the Bank holds an internal management buffer to cater for future unexpected growth and volatility in risk weighted exposures, as well as an estimation risk buffer. B. OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued 34 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 36 of 96 -- B.2 CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS continued The Group’s capital is defined as capital and reserves attributable to shareholders, as presented in the Group statement of Financial leverage ratio. As part of the capital management process, the Group monitors its capital structure by utilising various measures, one of which is the Financial Leverage Ratio (FLR). This ratio is calculated as total debt1 divided by total debt plus total equity. The Group’s strategy is to maintain a prudent FLR of 28.0% per the Group Risk Appetite statement. However, the 28.0% measure is merely a risk appetite indicator and does not necessarily indicate any form of a breach in terms of regulatory or covenant restrictions. The table below summarises the FLR position as at the end of the reporting period. With the adoption of IFRS 17, a significant amount of equity has been reallocated to contractual service margin (CSM) and risk adjustment. In line with developing market practice, this CSM balance, which is available for release to profit in future years or to absorb any adverse changes, is taken into account in the calculation of the FLR. The current limit of 28.0% remains conservative. R million Group 2025 Restated Group 20241 – Borrowings at amortised cost (refer to note A.5)2 16 105 17 517 Total debt2 16 105 17 517 Total equity 65 699 54 451 Total Contractual Service Margin (CSM)3 28 047 28 341 Financial leverage ratio % (50% CSM factored in) 16.8% 20.3% 1 The comparative information has been restated due to correction of a prior period error. Refer to note D1.1 for more detail. 2 Excluding all IFRS 16 lease liabilities of R3 941 million (2024: R4 145 million). 3 The CSM is net of reinsurance and net of tax. The FLR at 30 June 2025 is within Discovery’s risk appetite. Debt covenants The following are the key debt covenant ratios and their proximity to minimum requirements as per the contractual financial covenants. Debt covenant and explanation Minimum requirement Group 2025 Group 2024 Group Debt1 to EBITDA2 Ratio: Less than 2.5 times 1.02 times 1.4 times Group financial indebtedness to embedded value ■ Group financial indebtedness is as per Group Debt in the calculation. Less than 30% of Group Embedded value 13.3 % 16.7 % Discovery Life Statutory Capital Requirement (SCR) Cover SCR cover must be more than 1.1 1.9 times 1.8 times Group embedded value Greater than R30 billion R126 554 million R110 354 million New business embedded value must not be negative Positive value of new business for 3 consecutive 6-month periods June 2025: R1 201 million December 2024: R953 million June 2024: R1 148 million June 2024: R1 148 million December 2023: R684 million June 2023: R500 million 1 Group debt is contractually defined and means the aggregate consolidated financial indebtedness of the Group and excludes items such as the 1 Discovery Place (Discovery head office building in Sandton, South Africa) lease and includes guarantees issued to third parties. 2 EBITDA is contractually defined and specifically includes items such as dividends from associates, rental paid on 1 Discovery Place and excludes items deemed extraordinary and specified Financial Reinsurance (FinRe) arrangements. B. OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued 35 -- 37 of 96 -- B.3 IMPACT OF FINANCIAL RISK VARIANCES WITHIN THE SA LIFE AND UK LIFE OPERATING SEGMENTS The actuarial bases of Discovery Life and VitalityLife are actively maintained to ensure that the most up-to-date view of best- estimate expectations of the future is accurately reflected. In accordance with IFRS 17, financial risk assumptions are updated to reflect current market prices as at the reporting date. Discovery has elected, as permitted under IFRS 17, to recognise the impact of changes in these assumptions at the end of the reporting period within Other Comprehensive Income (OCI) for the specified portfolios. Consequently, changes in financial risk, including changes in the discount rate, do not directly affect the Group income statement due to this election. Instead, the effect of changes in financial risk during the period is recognised within net finance income and expenses from insurance contracts issued and reinsurance contracts held in OCI, with the cumulative effect presented in the Insurance Finance Reserve within equity. The balance of the Insurance Finance Reserve will be reclassified to profit or loss using a systematic rate over the life of the contract. The systematic rate is determined such that, over the lifetime of the contracts, the Insurance Finance Reserve reverts to zero. A summary of the movements in the Insurance Finance Reserve, net of reinsurance and net of tax, for the respective portfolios during the period is set out below. R million (Cumulative debit balance)/Cumulative credit balance SA Life Risk (GMM) SA Life: Group Life and Other (PAA) UK Life Risk (GMM) Total Balance at beginning of the period (7 004) 214 1 958 (4 832) Effects of changes in financial risk 934 48 922 1 904 Balance as at end of the period (6 070) 262 2 880 (2 928) B.4 CASH AND CASH EQUIVALENTS B.4.1 Group Statement of Cash Flows R million Reference Group 2025 Group 2024 Cash flows from operating activities i 8 667 2 733 Cash flows from investing activities (1 823) (1 886) Cash flows from financing activities ii (4 016) (780) Net increase in cash and cash equivalents 2 828 67 (i) The primary factors contributing to the improvement in cash flows from operating activities, which increased to R8 667 million in 2025 from R2 733 million in the previous year, are as follows: ■ An increase in organic cash generation driven by: – Discovery Life (both individual and CEB) delivering exceptional claims performances. – Discovery Insure experiencing benign weather conditions during the current financial year, in addition to improving non-weather -related claims experience. – Discovery Bank's improvement in operating losses coupled with fewer investments purchased in the current year. – Vitality Health's effective pricing actions, stabilising claims environment and tight claims and expense management. ■ Transitioning between Insurance Premium Tax Schemes in the UK, resulting in the deferment of payment to collections from policyholders rather than upfront at inception ■ Additional Value-in-Force (VIF) monetization in VitalityLife used to cover operational cashflow requirements and ensure the business maintained cash above its liquidity risk appetite ■ Net withdrawals in the prior year as VitalityInvest wound down (ii) Cash outflows from financing activities were R4 016 million (2024: R780 million) due to increased dividends paid to ordinary shareholders of R1 614 million (2024: R1 178 million) as well as net repayment of borrowings of R2 309 million (2024: R620 million net proceeds). The Group statement of cash flows includes cash flows relating to policyholders as well as those arising from the consolidated Discovery Unit Trusts and therefore to assist in the understanding of cash flows not distorted by policyholder flows, a Group shareholder free cash movement has been included in additional analyst information published on Discovery’s website. B. OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued 36 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 38 of 96 -- B.4 CASH AND CASH EQUIVALENTS continued B.4.2 Shareholder cash and cash equivalents R million Shareholder Unit-linked investment and insurance contracts1 Total Cash and cash equivalents at beginning of the year 14 154 4 811 18 965 Effects of exchange rate changes on cash and cash equivalents 173 – 173 Increase in cash and cash equivalents 2 889 (61) 2 828 Cash and cash equivalents at end of the year 17 216 4 750 21 966 1 Includes cash held within specific portfolios to match specific insurance liabilities. Included in shareholder cash, is the cash held in the Group’s insurance entities which is used to fund new business and match claims and other policyholder-related liabilities. This cash, together with the cash balances held by Discovery Bank of R6.3 billion (2024: R4.8 billion), although unencumbered, is held for specific purposes and therefore not considered available for distribution. The increase in cash and cash equivalents from these entities reflects in the Cash flow from operating activities in the Group statement of cash flows. Cash available to support Group liquidity requirements is R2.6 billion (2024: R2.1 billion). The Group also has undrawn revolving credit facilities of R2 billion at 30 June 2025. B.5 CONSOLIDATION OF DISCOVERY UNIT TRUSTS Unit trusts that the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into Discovery’s results for accounting purposes, which results in the recognition of the underlying assets and liabilities of each of the funds. As these policies are linked, the consolidation of the Discovery Unit Trusts has no impact on the net asset value for shareholders. Assets and liabilities of these Discovery Unit Trusts however increased by R3 940 million, compared to the prior financial year ended 30 June 2024, with movements in the following line items on the Group’s statement of financial position: R million Group 2025 Group 2024 Movements Investments at fair value through profit or loss 32 100 28 192 3 908 Contract receivables and other receivables 1 198 1 184 14 Cash and cash equivalents 2 743 2 735 8 Other assets 11 1 10 Total change in assets 36 052 32 112 3 940 Third-party interest in consolidated funds 35 357 31 456 3 901 Borrowings at amortised costs (bank overdraft) 2 6 (4) Other payables and provisions 605 693 (88) Liabilities arising from insurance contracts issued 73 (47) 120 Other liabilities 15 4 11 Total change in liabilities 36 052 32 112 3 940 There are significant trade volumes in the underlying funds of Discovery Unit Trusts. The net cash inflow of the movement in policyholder investments for the period is R966 million and has been included in the ‘Increase in operating assets’ line item on the Group’s statement of cash flows. B. OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued 37 -- 39 of 96 -- B.6 MATERIAL TRANSACTIONS WITH RELATED PARTIES Discovery Long-term Incentive Plan Trust At the Annual General Meeting (AGM) held on 28 November 2019, the shareholders approved the establishment of the Discovery Long- term Incentive Plan Trust (Trust) with the purpose, inter alia, to subscribe, purchase and/or otherwise acquire and hold Discovery ordinary shares from time to time for the benefit of the share-based payment plan for employees, in accordance with the requirements of the Trust. During the year ended 30 June 2025, 3 306 749 (2024: 3 227 675) new shares were issued by Discovery Limited to the Trust at a value of R626 million (2024: R432 million). In addition, during the year ended 30 June 2025, shares of 5 402 773 (2024: 3 660 857) vested with participants. In terms of IFRS Accounting Standards, while held in the Trust, these shares are treated as treasury shares and not treated as issued for accounting purposes. B.7 MAJOR CUSTOMERS AND OTHER DISCOVERY ENTITIES NOT PART OF DISCOVERY GROUP Discovery Health Medical Scheme (DHMS) Discovery Health administers DHMS and provides managed care services, for which it charges an administration fee and a managed healthcare fee, respectively. These fees are determined on an annual basis and approved by the trustees of DHMS. The fees totalled R8 386 million for the year ended 30 June 2025 (2024: R7 940 million). Discovery offers the members of DHMS access to the Vitality programme. B.8 CHANGES IN DIRECTORATE Changes to the Board of Discovery Limited from 1 July 2024 to the date of this announcement are as follows: ■ Mr Tito Titus Mboweni, an independent non-executive of Discovery, passed away on 12 October 2024. The late Mr Mboweni was a member of the Nominations, Remuneration and the Risk and Compliance Committees respectively. These committees remain quorate. ■ Ms VN Fakude has been appointed as an independent non-executive director with effect from 1 September 2025. She is a member of the Discovery Limited Nominations, Remuneration and Social and Ethics Committees. Her appointment will further augment the Board’s global business experience and expertise while improving its diversity. B.9 EVENTS AFTER REPORTING DATE The following non-adjusting events occurred between the end of the reporting period and the date when the financial results were authorised for issue. B. OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued 38 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 40 of 96 -- B.9 EVENTS AFTER REPORTING DATE continued B.9.1 Dividend declaration in respect of the year ended 30 June 2025 B PREFERENCE SHARE CASH DIVIDEND DECLARATION On Thursday, 4 September 2025, the Board of directors declared a final gross cash dividend of 545.47945 cents (436.38356 cents net of dividend withholding tax) per B preference share for the period 1 January 2025 to 30 June 2025, payable from the income reserves of the Company. A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt. The issued preference share capital at the declaration date is 8 million B preference shares. The salient dates for the dividend will be as follows: Last day of trade to receive a dividend Monday, 22 September 2025 Shares commence trading “ex” dividend Tuesday, 23 September 2025 Record date Friday, 26 September 2025 Payment date Monday, 29 September 2025 B preference share certificates may not be dematerialised or rematerialised between Tuesday, 23 September 2025 and Friday, 26 September 2025, both days inclusive. ORDINARY SHARE CASH DIVIDEND DECLARATION On Wednesday, 10 September 2025 the Board of Directors declared a final gross cash dividend of 201.00000 cents (160.80000 cents net of dividend withholding tax) per ordinary share, out of the income reserves of the company. A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt. The number of ordinary shares in issue at the date of declaration is 679 680 841. The salient dates for the dividend will be as follows: Last day of trade to receive a dividend Tuesday, 14 October 2025 Shares commence trading “ex” dividend Wednesday, 15 October 2025 Record date Friday, 17 October 2025 Payment date Monday, 20 October 2025 Ordinary share certificates may not be dematerialised or rematerialised between Wednesday, 15 October 2025 and Friday, 17 October 2025, both days inclusive. B. OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued 39 -- 41 of 96 -- SECTION C INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE 41 C.1.1 Insurance and reinsurance contracts disclosures and reconciliations 45 C.1.2.1 Summary of insurance contracts issued and reinsurance contracts held 46 C.1.2.2 Movement in insurance contract balances: GMM 52 C.1.2.3 Movement in insurance contract balances: VFA 54 C.1.2.4 Movement in reinsurance contract balances: GMM 58 C.1.2.5 Insurance revenue 60 C.1.2.6 Net investment result 64 C.1.2.7 Effect of contracts initially recognised in the period 40 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 42 of 96 -- C.1.1 INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND RECONCILIATIONS The following disclosures enable the user to assess the effect of insurance contracts issued and reinsurance contracts held on Discovery’s financial position, financial performance and cash flows. Introduction To assist the users of the financial statements in understanding the insurance and reinsurance disclosures, Section C disclosures have been re-presented for the following: 1. The Discovery SA Life and Invest (Risk) (GMM) portfolio has been split into two separate portfolios —SA Life (Risk) (GMM) and SA Invest (Risk) (GMM). This change is purely a re-presentation of the information, with no impact on the total values reported in the SA Life and SA Invest disclosures. The purpose of this split is to provide users of the financial statements with a clearer view of the movements within each portfolio during the reporting period. By presenting SA Life (Risk) (GMM) and SA Invest (Risk) (GMM) separately, the users of the financial statements can better understand the distinct performance and financial impact of each portfolio during the reporting period. 2. The net investment note has been updated to provide a granular breakdown of the key components driving the interest accretion as presented in profit or loss and OCI. The change is aimed at providing the users of the financial statements a better understanding of the detailed interest accretion components. 3. The comparative disclosures for the Discovery SA Life (Risk) (GMM) portfolio has been restated due to a correction of a prior period error, refer to section D for more detail. Refer to the index summary table for all the notes that have been restated. IFRS 17 requires that in determining the level at which an aggregated group of insurance contracts can provide useful information to the user, Discovery considers: ■ The type of contract that would consider the nature of the product and the measurement model. ■ The geographical areas may expose the entity to different sets of risks, even for similar products. ■ Reportable segments. Having applied the guidance, Discovery has aggregated its portfolios for the disclosures as set out below. C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 41 Results commentary Group statement of financial position Group income statement Group statement of other comprehensive income Group statement of cash flows Group statement of changes in equity Notes to the condensed consolidated financial statements Other significant items in these results Insurance and reinsurance contract related disclosures Restatements Accounting policies Embedded value statement Annexure A Administration SA Life (Risk) | GMM (Life: Individual Life, Dollar LifePlan, Health Protection Plans, Standalone Global Educator) SA Invest (Risk) | GMM (Guaranteed endowments) SA Invest (Participating) | VFA (Unit-linked invest products, Unit-linked insurance products and Discovery Retirement Optimiser) SA Life and Invest: Group Life and other | PAA (Group Risk, Funeral and other including Discovery Card Protector, Standalone Cancer Protector and LifeDrive) SA Insure and other | PAA (Personal and Commercial lines, GAP and Trauma Cover, Travel Cover and AfricaHealth) UK Life (Risk) | GMM (Own Licence and PAC book) UK Health | PAA (Private Medical Insurance) -- 43 of 96 -- C.1.1 INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND RECONCILIATIONS continued The following index is a summary of all the quantitative disclosures set out in the notes: Note Description Analysis of financial position C.1.2.1 Summary of insurance contracts issued and reinsurance contracts held1,2 The note summarises the total value of insurance and reinsurance contracts held across the disclosed portfolios, showing separately those insurance and reinsurance contracts in a net liability or net asset position. Reconciliation of insurance contracts Analysis by measurement component GMM C.1.2.2.1 SA Life (Risk)1,2,3 C.1.2.2.2 SA Invest (Risk)1,2 C.1.2.2.3 UK Life (Risk) VFA C.1.2.3.1 SA Invest (Participating) Reconciliation of reinsurance contracts Analysis by measurement component GMM C.1.2.4.1 SA Life (Risk)3 C.1.2.4.2 UK Life (Risk) The notes provide a detailed reconciliation of disclosed portfolios showing the build-up of the measurement components, namely: ■ Estimates of the present value of expected fulfilment cash flows. ■ The Risk adjustment. ■ The Contractual service margin reflects unearned profit. The CSM is further separated to reflect how the CSM was calculated at transition, being modified retrospectively or fully retrospectively. 1 The comparative information has been restated due to correction of a prior period error. Refer to item 3 noted in the introduction of section C. 2 The note has been re-presented for the split of the Discovery SA Life and Invest (Risk) (GMM) portfolio. Refer to item 1 noted in the introduction of section C. 3 The note has been re-presented to provide a granular breakdown of interest accretion components. Refer to item 2 noted in the introduction of section C. C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 42 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 44 of 96 -- C.1.1 INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND RECONCILIATIONS continued Note Description Analysis of income statement C.1.2.5 Insurance revenue1,2,3 The note provides a breakdown of the makeup of insurance revenue for each disclosed portfolio business unit. For those contracts not measured using the PAA approach, the amount reflects the provision of services and the recovery of insurance acquisition cash flows. The provision of services is represented by the change in the LRC, namely: ■ CSM recognised during the period for the service provided. ■ The change in the risk adjustment for non-financial risk. ■ Expected claims and insurance services expenses. ■ Experience adjustments. C.1.2.6 Net investment result1,2 The note provides a holistic view of the following: ■ The investment returns on financial assets held. ■ The insurance and reinsurance finance income and expenses, including the amounts recognised in profit or loss and other comprehensive income (OCI). Additional information Effect of contracts initially recognised in the period: C.1.2.7 Effect of insurance contracts initially recognised in the year2 . C.1.2.7 Effect of reinsurance contracts initially recognised in the year2 . The notes provide a breakdown of the contracts initially recognised during the period for each disclosed portfolio business unit. ■ For insurance contracts, differentiate between profitable contracts recognised with CSM and onerous contracts. ■ Reinsurance contracts reflect contracts originated with and without the loss-recovery component. 1 The comparative information has been restated due to correction of a prior period error. Refer to item 3 noted in the introduction of section C. 2 The note has been re-presented for the split of the Discovery SA Life and Invest (Risk) (GMM) portfolio. Refer to item 1 noted in the introduction of section C. 3 The note has been re-presented to provide a granular breakdown of interest accretion components. Refer to item 2 noted in the introduction of section C. C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 43 Results commentary Group statement of financial position Group income statement Group statement of other comprehensive income Group statement of cash flows Group statement of changes in equity Notes to the condensed consolidated financial statements Other significant items in these results Insurance and reinsurance contract related disclosures Restatements Accounting policies Embedded value statement Annexure A Administration -- 45 of 96 -- C.1.1 INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND RECONCILIATIONS continued Definitions and Abbreviations The following abbreviations and terms are commonly used within the accounting policy: Abbreviation or definition Meaning CSM Contractual Service Margin DISCOVERY Discovery Group DPF Direct Participation Features DRO Discovery Retirement Optimiser EFCF Expected Fulfilment Cash Flows FINANCIAL RISK The risk of a possible future change in one or more of a specified interest rate, financial instrument price, commodity price, currency exchange rate, index of prices or rates, credit rating or credit index or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract. GMM General Measurement Model IACF Insurance Acquisition Cash Flows IFIE Insurance finance income and expense comprises of the change in the carrying amount of the group of insurance contracts arising from: ■ The effect of the time value of money and changes in the time value of money, and ■ The effect of financial risk and changes in financial risk IFRS IFRS® Accounting Standards IFRS 17 IFRS 17 Insurance Contracts (effective for Discovery post 1 July 2023) IFRS 17 margins IFRS 17 margins refers to the contractual service margin plus the risk adjustment ISE Insurance Service Expenses LIC Liability for Incurred Claims LRC Liability for Remaining Coverage OCI Other Comprehensive Income PAA Premium Allocation Approach VFA Variable Fee Approach C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 44 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 46 of 96 -- C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND RECONCILIATIONS C.1.2.1 Summary of insurance contracts issued and reinsurance contracts held Group R million (Assets)/Liabilities Navigation SA Life Risk (GMM) SA Invest Risk (GMM) UK Life Risk (GMM) SA Invest Partici- pating (VFA) SA Life: Group Life and other (PAA) SA Insure and other (PAA) UK Health (PAA) Total Year ended 30 June 2025 Insurance Contracts A = D + E (23 002) 23 580 (20 180) 88 150 6 414 734 (4 865) 70 831 Reinsurance Contracts B = F 370 – 8 751 – (865) (84) (13) 8 159 Total C = A +B (22 632) 23 580 (11 429) 88 150 5 549 650 (4 878) 78 990 Insurance contracts issued Assets arising from insurance contracts – Insurance contract balances (23 002) – (20 180) – – – 884 (42 298) – Assets for insurance acquisition cash flows – – – – – – (5 749) (5 749) Total D (23 002) – (20 180) – – – (4 865) (48 047) Liabilities arising from insurance contracts – Insurance contract balances – 23 580 – 88 150 6 414 734 – 118 878 Total E – 23 580 – 88 150 6 414 734 – 118 878 Reinsurance contracts held Reinsurance contract assets – – – – (865) (84) (13) (962) liabilities 370 – 8 751 – – – – 9 121 Total F 370 – 8 751 – (865) (84) (13) 8 159 Year ended 30 June 2024 Insurance Contracts (17 846) 24 565 (15 269) 73 721 5 888 896 (4 224) 67 731 Reinsurance Contracts 126 – 5 270 – (685) (139) (13) 4 559 Total (17 720) 24 565 (9 999) 73 721 5 203 757 (4 237) 72 290 Insurance contracts issued Assets arising from insurance contracts – Insurance contract balances (17 846) – (15 269) – – – 683 (32 432) – Assets for insurance acquisition cash flows – – – – – – (4 907) (4 907) Total (17 846) – (15 269) – – – (4 224) (37 339) Liabilities arising from insurance contracts – Insurance contract balances – 24 565 – 73 721 5 888 896 – 105 070 – 24 565 – 73 721 5 888 896 – 105 070 Reinsurance contracts held Reinsurance contract assets – – – – (685) (139) (13) (837) Reinsurance contract liabilities 126 – 5 270 – – – – 5 396 Total 126 – 5 270 – (685) (139) (13) 4 559 Cross reference to related notes of insurance contracts issued – Analysis by measurement component C.1.2.2.1 C.1.2.2.2 C.1.2.2.3 C.1.2.3 Cross reference to related notes of reinsurance contracts held – Analysis by measurement component C.1.2.4.1 C.1.2.4.2 C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 45 Results commentary Group statement of financial position Group income statement Group statement of other comprehensive income Group statement of cash flows Group statement of changes in equity Notes to the condensed consolidated financial statements Other significant items in these results Insurance and reinsurance contract related disclosures Restatements Accounting policies Embedded value statement Annexure A Administration -- 47 of 96 -- C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND RECONCILIATIONS continued C.1.2.2 Movement in insurance contract balances: GMM C.1.2.2.1 SA LIFE (RISK) ANALYSIS BY MEASUREMENT COMPONENT 2025 Group R million (Assets)/Liabilities RA for non- financial Risk CSM Navigation Estimates of PVFCF Other contracts Total Opening assets arising from insurance contracts issued (54 499) 7 811 28 842 (17 846) Net balance at beginning of the year A (54 499) 7 811 28 842 (17 846) Changes in the income statement and OCI Changes that relate to current services CSM recognised for services provided – – (1 862) (1 862) Change in Risk Adjustment for non-financial risk that relates to expired risk – (642) – (642) Experience adjustments (724) – – (724) Changes that relate to future services Contracts initially recognised in the period (1 647) 395 1 286 34 Changes in estimates that adjust CSM 4 046 (362) (3 684) – Changes in estimates that result in onerous contract losses or reversal of losses 202 (14) – 188 Servicing expenses and commission for onerous contracts 13 – – 13 Changes that relate to past services Adjustment to liability for incurred claims – 6 – 6 Insurance service result B 1 890 (617) (4 260) (2 987) Net finance expenses from insurance contracts C (8 647) 1 163 2 713 (4 771) Net changes to income statement and OCI D = B + C (6 757) 546 (1 547) (7 758) Cash flows E 2 602 – – 2 602 Net balance at the end of the year G = A + D + E (58 654) 8 357 27 295 (23 002) Closing assets arising from insurance contracts issued (58 654) 8 357 27 295 (23 002) Net balance at the end of the year (58 654) 8 357 27 295 (23 002) C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 46 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 48 of 96 -- 2024 RA for non– financial Risk CSM Estimates of PVFCF Other contracts Total (52 454) 6 960 30 838 (14 656) (52 454) 6 960 30 838 (14 656) – – (1 800) (1 800) – (593) – (593) 656 – – 656 (1 888) 402 1 522 36 4 024 369 (4 393) – (337) (9) (6) (352) 26 – – 26 – 37 – 37 2 481 206 (4 677) (1 990) (6 366) 645 2 681 (3 040) (3 885) 851 (1 996) (5 030) 1 840 – – 1 840 (54 499) 7 811 28 842 (17 846) (54 499) 7 811 28 842 (17 846) (54 499) 7 811 28 842 (17 846) 47 -- 49 of 96 -- C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND RECONCILIATIONS continued C.1.2.2 Movement in insurance contract balances: GMM continued C.1.2.2.2 SA INVEST (RISK) ANALYSIS BY MEASUREMENT COMPONENT 2025 Group R million (Assets)/Liabilities RA for non- financial Risk CSM Navigation Estimates of PVFCF Other contracts Total Opening liabilities arising from insurance contracts issued 23 489 135 941 24 565 Net balance at beginning of the year A 23 489 135 941 24 565 Changes in the income statement and OCI Changes that relate to current services CSM recognised for services provided – – (395) (395) Change in Risk Adjustment for non- financial risk that relates to expired risk – (38) – (38) Experience adjustments 32 – – 32 Changes that relate to future services Contracts initially recognised in the period (266) 25 245 4 Changes in estimates that adjust CSM 49 17 (66) – Changes in estimates that result in onerous contract losses or reversal of losses (5) 23 – 18 Servicing expenses and commission for onerous contracts – – – – Changes that relate to past services Adjustment to liability for incurred claims – – – – Insurance service result B (190) 27 (216) (379) Net finance expenses from insurance contracts C 2 805 28 95 2 928 Net changes to income statement and OCI D = B + C 2 615 55 (121) 2 549 Cash flows E (3 534) – – (3 534) Net balance at the end of the year G = A + D + E 22 570 190 820 23 580 Closing liabilities arising from insurance contracts issued 22 570 190 820 23 580 Net balance at the end of the year 22 570 190 820 23 580 C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 48 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 50 of 96 -- 2024 RA for non- financial Risk CSM Estimates of PVFCF Other contracts Total 21 521 86 814 22 421 21 521 86 814 22 421 – – (295) (295) – (23) – (23) 7 – – 7 (369) 27 365 23 15 11 (26) – 22 10 – 32 – – – – – – – – (325) 25 44 (256) 2 234 24 83 2 341 1 909 49 127 2 085 59 – – 59 23 489 135 941 24 565 23 489 135 941 24 565 23 489 135 941 24 565 49 -- 51 of 96 -- C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND RECONCILIATIONS continued C.1.2.2 Movement in insurance contract balances: GMM continued C.1.2.2.3 UK LIFE (RISK) ANALYSIS BY MEASUREMENT COMPONENT 2025 Group R million (Assets)/Liabilities RA for non- financial Risk CSM Navigation Estimates of PVFCF Other contracts Total Opening assets arising from insurance contracts issued (30 819) 2 239 13 311 (15 269) Net balance at beginning of the year A (30 819) 2 239 13 311 (15 269) Changes in the income statement and OCI Changes that relate to current services CSM recognised for services provided – – (1 332) (1 332) Change in Risk Adjustment for non- financial risk that relates to expired risk – (246) – (246) Experience adjustments 362 – – 362 Changes that relate to future services Contracts initially recognised in the period (2 192) 471 2 128 407 Changes in estimates that adjust CSM (164) (2) 166 – Changes in estimates that result in onerous contract losses or reversal of losses 345 9 – 354 Insurance service result B (1 649) 232 962 (455) Net finance expenses from insurance contracts C (2 178) (39) 298 (1 919) Net changes to income statement and OCI D = B + C (3 827) 193 1 260 (2 374) Cash flows E (1 553) – – (1 553) Effect of movements in exchange rates F (1 892) 130 778 (984) Net balance at the end of the year G = A + D + E + F (38 091) 2 562 15 349 (20 180) Closing assets arising from insurance contracts issued (38 091) 2 562 15 349 (20 180) Net balance at the end of the year (38 091) 2 562 15 349 (20 180) C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 50 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 52 of 96 -- 2024 RA for non- financial Risk CSM Estimates of PVFCF Other contracts Total (27 886) 2 020 13 807 (12 059) (27 886) 2 020 13 807 (12 059) – – (1 242) (1 242) – (209) – (209) 224 – – 224 (1 573) 368 1 482 277 447 (3) (444) – 224 39 – 263 (678) 195 (204) (687) (3 108) 107 239 (2 762) (3 786) 302 35 (3 449) (300) – – (300) 1 153 (83) (531) 539 (30 819) 2 239 13 311 (15 269) (30 819) 2 239 13 311 (15 269) (30 819) 2 239 13 311 (15 269) 51 -- 53 of 96 -- C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND RECONCILIATIONS continued C.1.2.3 Movement in insurance contract balances: VFA C.1.2.3.1 SA INVEST (PARTICIPATING) ANALYSIS OF MEASUREMENT COMPONENT 2025 CSM Group R million (Assets)/Liabilities Navigation Estimates of PVFCF RA for non- financial Risk Transition: Modified retro- spective Other contracts Total Opening liabilities arising from insurance contracts issued 66 642 773 5 275 1 031 73 721 Net balance at beginning of the year A 66 642 773 5 275 1 031 73 721 Changes in the income statement and OCI Changes that relate to current services CSM recognised for services provided – – (1 058) (266) (1 324) Change in Risk Adjustment for non- financial risk that relates to expired risk – (186) – – (186) Experience adjustments (96) – 56 (22) (62) Changes that relate to future services Contracts initially recognised in the period (764) 89 – 732 57 Changes in estimates that adjust CSM (357) 99 202 56 – Changes in estimates that result in onerous contract losses or reversal of losses 6 1 – – 7 Insurance service result B (1 211) 3 (800) 500 (1 508) Net finance expenses from insurance contracts C 11 855 67 902 200 13 024 Net changes to income statement and OCI D = B + C 10 644 70 102 700 11 516 Cash flows E 2 913 – – – 2 913 Net balance at the end of the year G = A + D + E 80 199 843 5 377 1 731 88 150 Closing liabilities arising from insurance contracts issued 80 199 843 5 377 1 731 88 150 Net balance at the end of the year 80 199 843 5 377 1 731 88 150 C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 52 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 54 of 96 -- 2024 CSM Estimates of PVFCF RA for non- financial Risk Transition: Modified retro- spective Other contracts Total 59 328 912 5 430 638 66 308 59 328 912 5 430 638 66 308 – – (1 080) (142) (1 222) – (212) – – (212) (93) – 63 1 (29) (510) 70 – 490 50 289 (83) (122) (84) – (23) 1 – – (22) (337) (224) (1 139) 265 (1 435) 6 613 85 984 128 7 810 6 276 (139) (155) 393 6 375 1 038 – – – 1 038 66 642 773 5 275 1 031 73 721 66 642 773 5 275 1 031 73 721 66 642 773 5 275 1 031 73 721 53 -- 55 of 96 -- C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND RECONCILIATIONS continued C.1.2.4 Movement in reinsurance contract balances: GMM C.1.2.4.1 SA LIFE (RISK) ANALYSIS BY MEASUREMENT COMPONENT 2025 CSM Group R million (Assets)/Liabilities Navigation Estimates of PVFCF RA for non- financial Risk Transition: Modified retro- spective Other contracts Total Opening liabilities arising from reinsurance contracts held 5 899 (703) (100) (4 970) 126 Net balance at beginning of the year A 5 899 (703) (100) (4 970) 126 Changes in the income statement and OCI Changes that relate to current services CSM recognised for services provided – – 6 319 325 Change in Risk Adjustment for non-financial risk that relates to expired risk – 73 – – 73 Experience adjustments 624 – – – 624 Changes that relate to future services Contracts initially recognised in the period 187 (21) – (172) (6) Changes in estimates that adjust CSM (897) 76 3 839 21 Changes in estimates that relate to losses and reversal of losses on underlying contracts (19) (2) – – (21) Changes that relate to past services Adjustment to assets for incurred claims – (1) – – (1) Net Expenses from reinsurance contracts held B (105) 125 9 986 1 015 Net finance income from reinsurance contracts C 1 035 (93) (13) (520) 409 Net changes to income statement and OCI D = B + C 930 32 (4) 466 1 424 Cash flows E (1 180) – – – (1 180) Effect of movements in exchange rates F – – – – – Net balance at the end of the year G = A + D + E + F 5 649 (671) (104) (4 504) 370 Closing liabilities arising from reinsurance contracts held 5 649 (671) (104) (4 504) 370 Net balance at the end of the year 5 649 (671) (104) (4 504) 370 C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 54 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 56 of 96 -- 2024 CSM Estimates of PVFCF RA for non- financial Risk Transition: Modified retro- spective Other contracts Total 6 094 (698) (80) (4 749) 567 6 094 (698) (80) (4 749) 567 – – 6 338 344 – 71 – – 71 (12) – – – (12) – 202 (22) – (186) (6) 16 – (16) 40 40 (17) 4 – – (13) – (10) – – (10) 189 43 (10) 192 414 537 (48) (10) (413) 66 726 (5) (20) (221) 480 (921) – – – (921) – – – – – 5 899 (703) (100) (4 970) 126 5 899 (703) (100) (4 970) 126 5 899 (703) (100) (4 970) 126 55 -- 57 of 96 -- C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND RECONCILIATIONS continued C.1.2.4 Movement in reinsurance contract balances: GMM continued C.1.2.4.2 UK LIFE (RISK) ANALYSIS BY MEASUREMENT COMPONENT 2025 RA for non- financial Risk CSM Group R million (Assets)/Liabilities Navigation Estimates of PVFCF Other contracts Total Opening liabilities arising from reinsurance contracts held 11 460 (471) (5 719) 5 270 Net balance at beginning of the year A 11 460 (471) (5 719) 5 270 Changes in the income statement and OCI Changes that relate to current services CSM recognised for services provided – – 636 636 Change in Risk Adjustment for non- financial risk that relates to expired risk – 25 – 25 Experience adjustments (130) – – (130) Changes that relate to future services Contracts initially recognised in the period 1 574 (76) (1 782) (284) Changes in estimates that adjust CSM 333 (2) (331) – Changes in estimates that relate to losses and reversal of losses on underlying contracts (81) (4) – (85) Net Expenses from reinsurance contracts held B 1 696 (57) (1 477) 162 Net finance income from reinsurance contracts C 598 34 (180) 452 Net changes to income statement and OCI D = B + C 2 294 (23) (1 657) 614 Cash flows E 2 460 – – 2 460 Effect of movements in exchange rates F 809 (27) (375) 407 Net balance at the end of the year G = A + D + E + F 17 023 (521) (7 751) 8 751 Closing liabilities arising from reinsurance contracts held 17 023 (521) (7 751) 8 751 Net balance at the end of the year 17 023 (521) (7 751) 8 751 C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 56 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 58 of 96 -- 2024 CSM Estimates of PVFCF RA for non-financial Risk Other contracts Total 9 701 (429) (5 020) 4 252 9 701 (429) (5 020) 4 252 – – 495 495 – 24 – 24 22 – – 22 1 193 (65) (1 318) (190) (30) (2) 33 1 63 (8) – 55 1 248 (51) (790) 407 743 (8) (119) 616 1 991 (59) (909) 1 023 183 – – 183 (415) 17 210 (188) 11 460 (471) (5 719) 5 270 11 460 (471) (5 719) 5 270 11 460 (471) (5 719) 5 270 57 -- 59 of 96 -- C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND RECONCILIATIONS continued C.1.2.5 Insurance revenue The following tables present an analysis of the insurance revenue recognised in the period. Group R million (Income/(expense)) Year ended 30 June 2025 Contracts not measured under the PAA Amounts relating to changes in liabilities for remaining coverage – CSM recognised for services provided – Change in risk adjustment for non-financial risk for risk expired – Expected incurred claims and other insurance service expenses – Experience adjustments Recovery of insurance acquisition cash flows Contracts not measured under the PAA Contracts measured under the PAA Total insurance revenue Year ended 30 June 2024 Contracts not measured under the PAA Amounts relating to changes in liabilities for remaining coverage – CSM recognised for services provided – Change in risk adjustment for non-financial risk for risk expired – Expected incurred claims and other insurance service expenses – Experience adjustments Recovery of insurance acquisition cash flows Contracts not measured under the PAA Contracts measured under the PAA Total insurance revenue C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 58 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 60 of 96 -- SA Life Risk (GMM) SA Invest Risk (GMM) SA Invest Participating (VFA) SA Life: Group life and other (PAA) SA Insure and other (PAA) UK Life Risk (GMM)1 UK Health (PAA) Total 13 257 975 2 574 – – 5 014 – 21 820 1 862 395 1 324 – – 1 332 – 4 913 640 36 167 – – 239 – 1 082 10 712 502 986 – – 3 565 – 15 765 43 42 97 – – (122) – 60 2 162 228 783 – – 3 036 – 6 209 15 419 1 203 3 357 – – 8 050 – 28 029 – – – 3 738 6 822 – 19 124 29 684 15 419 1 203 3 357 3 738 6 822 8 050 19 124 57 713 12 176 727 2 572 – – 4 294 – 19 769 1 800 295 1 222 – – 1 241 – 4 558 589 22 201 – – 201 – 1 013 9 880 370 1 074 – – 3 146 – 14 470 (93) 40 75 – – (294) – (272) 1 838 304 757 – – 2 610 – 5 509 14 014 1 031 3 329 – – 6 904 – 25 278 – – – 3 517 6 861 – 16 474 26 852 14 014 1 031 3 329 3 517 6 861 6 904 16 474 52 130 59 -- 61 of 96 -- C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND RECONCILIATIONS continued C.1.2.6 Net investment result The following table analyses the Group’s net investment result in profit or loss and OCI. Group R million (Income/(expense)) Year ended 30 June 2025 Investment return Interest revenue from financial assets not measured at FVTPL Net gains on FVTPL investments Total investment return Movement in investment contract liabilities Movement in third party interests in consolidated funds Finance income/(expenses) from insurance contracts Amounts recognised in profit or loss – Changes in fair value of underlying items of direct participation contracts – Interest accreted to the CSM – Interest on FCF and other finance (income)/expenses – Effect of changes in interest rates and other financial assumptions – Effect of movements in exchange rates Amounts recognised in OCI – Interest accreted to the CSM – Interest on FCF and other finance (income)/expenses – Effect of changes in interest rates and other financial assumptions – Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition – Effect of movements in exchange rates Net finance expenses from insurance contracts Finance income/(expenses) from reinsurance contracts Amounts recognised in profit or loss – Interest accreted to the CSM – Interest on FCF and other finance (income)/expenses – Effect of changes in interest rates and other financial assumptions – Effect of movements in exchange rates Amounts recognised in OCI – Interest accreted to the CSM – Interest on FCF and other finance (income)/expenses – Effect of changes in interest rates and other financial assumptions – Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition – Effect of movements in exchange rates Net finance Income from reinsurance contracts C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 60 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 62 of 96 -- SA Life Risk (GMM) SA Invest Risk (GMM) SA Invest Participating (VFA) SA Life: Group Life and other (PAA) SA Insure and other immaterial (PAA) UK Life Risk (GMM) UK Health (PAA) Other businesses Total 3 – – – 5 76 154 760 998 29 2 986 13 130 503 – – 70 9 100 25 818 32 2 986 13 130 503 5 76 224 9 860 26 816 (3 810) (3 810) (4 394) (4 394) – – (13 024) – – – – – (13 024) (3 475) (95) (1 101) – – (258) – – (4 929) 6 562 (1 838) 1 101 (496) (20) 974 – – 6 283 – (995) – – – – – – (995) – – – – – – – – – 731 – – – – (40) – – 691 (2 465) – – 81 – 1 061 – – (1 323) 2 309 – – (10) – 125 – – 2 424 1 151 – – – – 57 – – 1 208 (42) – – 3 – – – – (39) 4 771 (2 928) (13 024) (422) (20) 1 919 – – (9 704) 509 – – – – 156 – – 665 (697) – – 64 – (455) – – (1 088) – – – – – – – – – – – – – – – – – – (44) – – – – 24 – – (20) 291 – – (8) – (260) – – 23 (229) – – 3 – 12 – – (214) (242) – – – – 71 – – (171) 3 – – (3) – – – – – (409) – – 56 – (452) – – (805) 61 -- 63 of 96 -- C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND RECONCILIATIONS continued C.1.2.6 Net investment result continued Group R million (Income/(expense)) Year ended 30 June 2024 Investment return Interest revenue from financial assets not measured at FVTPL Net gains on FVTPL investments Total investment return Movement in investment contract liabilities Movement in third party interests in consolidated funds Finance income/(expenses) from insurance contracts Amounts recognised in profit or loss – Changes in fair value of underlying items of direct participation contracts – Interest accreted to the CSM – Interest on FCF and other finance (income)/expenses – Effect of changes in interest rates and other financial assumptions – Effect of movements in exchange rates Amounts recognised in OCI – Interest accreted to the CSM – Interest on FCF and other finance (income)/expenses – Effect of changes in interest rates and other financial assumptions – Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition – Effect of movements in exchange rates Net finance expenses from insurance contracts Finance income/(expenses) from reinsurance contracts Amounts recognised in profit or loss – Interest accreted to the CSM – Interest on FCF and other finance (income)/expenses – Effect of changes in interest rates and other financial assumptions – Effect of movements in exchange rates Amounts recognised in OCI – Interest accreted to the CSM – Interest on FCF and other finance (income)/expenses – Effect of changes in interest rates and other financial assumptions – Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition – Effect of movements in exchange rates Net finance Income from reinsurance contracts C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 62 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 64 of 96 -- SA Life Risk (GMM) SA Invest Risk (GMM) SA Invest Participating (VFA) SA Life: Group Life and other (PAA) SA Insure and other immaterial (PAA) UK Life Risk (GMM) UK Health (PAA) Other businesses Total 22 – – – 234 58 160 386 860 (113) 2 356 7 843 506 1 – 60 5 592 16 245 (91) 2 356 7 843 506 235 58 220 5 978 17 105 (2 142) (2 142) (2 873) (2 873) – – (7 789) – – – – – (7 789) (3 397) (83) (1 112) – – (208) – – (4 800) 6 675 (1 876) 1 091 (458) – 587 – – 6 019 – (382) – – – – – – (382) – – – – – – – – – 662 – – – – (31) – – 631 (2 478) – – 77 – 1 056 – – (1 345) 381 – – 40 – 1 402 – – 1 823 1 242 – – – – (44) – – 1 198 (45) – – 5 – – – – (40) 3 040 (2 341) (7 810) (336) – 2 762 – – (4 685) 477 – – – – 100 – – 577 (736) – – 64 – (248) – – (920) – – – – – – – – – – – – – – – – – – (48) – – – – 18 – – (30) 206 – – (12) – (346) – – (152) (88) – – 2 – (166) – – (252) 121 – – – – 26 – – 147 2 – – (5) – – – – (3) (66) – – 49 – (616) – – (633) 63 -- 65 of 96 -- C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND RECONCILIATIONS continued C.1.2.7 Effect of contracts initially recognised in the period INSURANCE CONTRACTS Group R million Assets/(Liabilities) Year ended 30 June 2025 Insurance acquisition cash flows Claims and other insurance service expenses payable Estimates of present value of cash outflows Estimates of present value of cash inflows Risk adjustment for non-financial risk CSM Losses recognised on initial recognition Year ended 30 June 2024 Insurance acquisition cash flows Claims and other insurance service expenses payable Estimates of present value of cash outflows Estimates of present value of cash inflows Risk adjustment for non-financial risk CSM Losses recognised on initial recognition C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 64 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 66 of 96 -- Profitable contracts issued Onerous contracts issued SA Life Risk (GMM) SA Invest Risk (GMM) SA Invest Participating (VFA) UK Life Risk (GMM) SA Invest Risk (GMM) SA Life Risk (GMM) SA Invest Participating (VFA) UK Life Risk (GMM) Total (1 465) (160) (567) (4 956) (112) (11) (87) (1 276) (8 634) (2 050) (3 640) (9 543) (7 284) (180) (215) (840) (2 918) (26 670) (3 515) (3 800) (10 110) (12 240) (292) (226) (927) (4 194) (35 304) 5 176 4 063 10 913 14 760 278 229 888 3 866 40 173 (375) (18) (71) (392) (20) (7) (18) (79) (980) (1 286) (245) (732) (2 128) – – – – (4 391) – – – – (34) (4) (57) (407) (502) (1 290) (192) (421) (3 766) (111) (16) (113) (1 022) (6 931) (2 564) (4 652) (5 973) (4 994) (268) (377) (1 834) (2 090) (22 752) (3 854) (4 844) (6 394) (8 760) (379) (393) (1 947) (3 112) (29 683) 5 758 5 226 6 940 10 549 363 380 1 911 2 897 34 024 (382) (16) (56) (307) (21) (11) (14) (62) (868) (1 522) (366) (490) (1 482) – – – – (3 860) – – – – (37) (24) (50) (277) (388) 65 -- 67 of 96 -- C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND RECONCILIATIONS continued C.1.2.7 Effect of contracts initially recognised in the period continued REINSURANCE CONTRACTS Group R million Assets/(Liabilities) Group of contracts with a net cost on initial recognition1 SA Life Risk (GMM) UK Life Risk (GMM) Total Year ended 30 June 2025 Estimates of present value of cash outflows (1 032) (13 919) (14 951) Estimates of present value of cash inflows 845 12 345 13 190 Risk adjustment for non-financial Risk 21 76 97 Income recognised on initial recognition (for offset) (6) (284) (290) CSM (172) (1 782) (1 954) Year ended 30 June 2024 Estimates of present value of cash outflows (1 134) (9 103) (10 237) Estimates of present value of cash inflows 932 7 910 8 842 Risk adjustment for non-financial Risk 22 65 87 Income recognised on initial recognition (for offset) (6) (190) (196) CSM (186) (1 318) (1 504) 1 Group of contracts with a net cost on initial recognition refers to those reinsurance contracts with a CSM on initial recognition, that will reflect as a future cost relative to the insurance contract CSM that will release as future revenue. C. INSURANCE AND REINSURANCE CONTRACTS RELATED DISCLOSURE continued 66 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 68 of 96 -- SECTION D ADOPTION OF NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS 68 D.1.1 Restatement as a result of prior period errors identified 67 -- 69 of 96 -- The section provides information on the material new standards, amendments and interpretations that became effective for Discovery for its financial year commencing 1 July 2024. In addition, the section sets out the correction of prior period errors and the changes in presentation of specified line items. New standards and interpretation For the financial year commencing 1 July 2024, there were no material new standards, amendments or interpretations that became effective for Discovery. D.1.1 RESTATEMENT AS A RESULT OF PRIOR PERIOD ERRORS IDENTIFIED This section provides summary information of the impact as a result of the correction of prior period errors. The corrections impacted the Group statement of financial position as at 1 July 2023 and 30 June 2024, the Group income statement and Group statement of other comprehensive income for the year ended 30 June 2024 as well as the Group statement of cash flows for the year ended 30 June 2024. The information is set out to reconcile the previously published information to the final restated financial positions and performance. ITEM 1: CORRECTION OF SA LIFE AND SA INVEST INSURANCE RESULTS In the previous financial year ended 30 June 2024, Discovery adopted IFRS 17 Insurance Contracts for the first time, with full retrospective effect. The impacts of adoption of IFRS 17 were fully disclosed in the prior year’s financial statements. During the current year under review, Discovery identified the need to correct a coding error that impacted the quantification of the transitional impact of IFRS 17. This error affected the way in which the SA Life and SA Invest businesses accounted for changes in estimates. The correction resulted in a reallocation from the Insurance Finance Reserve, a component of equity, with a resultant increase in the Contractual Service Margin (CSM). As explained during transition to IFRS 17, the positive increase in CSM represents a “store of value” that is expected to release to the income statement, and ultimately to equity as retained earnings, over time. The CSM releases to the income statement as services are provided based on the coverage units of the underlying groups of insurance contracts. Notably, the strengthening of the CSM resulted in a decrease in the number of groups classified as onerous. The decrease in the onerous contract groups resulted in an increase in retained earnings as well as an increase in earnings of the prior year. The other measurement components of insurance contract balances, namely the present value of fulfilment cash flows and the risk adjustment, were unaffected by this correction. Importantly, the correction had a cumulative impact on the later years of the fully retrospective transition. Discovery corrected the error in the earliest period presented (1 July 2023) and in the comparative period ended 30 June 2024. The restatement has had no effect on operating, investing, or financing cash flows. While there was no overall impact on cash flows from operating activities, the correction resulted in an increase of R253 million in cash generated from operations, with an equal and opposite adjustment to operating liabilities. Consistent with the impacts explained upon transition, the restatement does not affect regulatory solvency positions or embedded value. D. ADOPTION OF NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued 68 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 70 of 96 -- D.1.1 RESTATEMENT AS A RESULT OF PRIOR PERIOD ERRORS IDENTIFIED continued RECONCILIATION OF THE RESTATED GROUP STATEMENT OF FINANCIAL POSITION AS AT 1 JULY 2023 R million Group 30 June 2023 (previously reported) Item 1 Correction Increase/ (Decrease) Group 30 June 2023 Restated Assets Assets arising from insurance contracts issued 33 624 (3 400) 30 224 – Estimates of PVFCF 80 340 – 80 340 – RA for non-financial Risk (8 981) – (8 981) – Contractual service margin (41 244) (3 400) (44 644) – Portfolios applying the PAA approach 3 509 – 3 509 Total of assets unaffected by restatement 225 115 – 225 115 TOTAL ASSETS 258 739 (3 400) 255 339 Equity Other reserves 4 690 (3 128) 1 562 Retained earnings 33 900 646 34 546 Total of equity unaffected by restatement 11 134 – 11 134 TOTAL EQUITY 49 724 (2 482) 47 242 Liabilities Deferred liability 6 706 (918) 5 788 Total of liabilities unaffected by restatement 202 309 – 202 309 TOTAL LIABILITIES 209 015 (918) 208 097 TOTAL EQUITY AND LIABILITIES 258 739 (3 400) 255 339 RECONCILIATION OF THE RESTATED GROUP STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2024 R million Group 30 June 2024 (previously reported) Item 1 Correction Increase/ (Decrease) Group 30 June 2024 Restated Assets Assets arising from insurance contracts issued 41 816 (4 477) 37 339 – Estimates of PVFCF 85 318 – 85 318 – RA for non-financial Risk (10 050) – (10 050) – Contractual service margin (37 676) (4 477) (42 153) – Portfolios applying the PAA approach 4 224 – 4 224 Total of assets unaffected by restatement 242 295 – 242 295 TOTAL ASSETS 284 111 (4 477) 279 634 Equity Other reserves 6 275 (4 099) 2 176 Retained earnings 39 998 831 40 829 Total of equity unaffected by restatement 11 446 – 11 446 TOTAL EQUITY 57 719 (3 268) 54 451 Liabilities Deferred liability 8 184 (1 209) 6 975 Total of liabilities unaffected by restatement 218 208 – 218 208 TOTAL LIABILITIES 226 392 (1 209) 225 183 TOTAL EQUITY AND LIABILITIES 284 111 (4 477) 279 634 D. ADOPTION OF NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued 69 -- 71 of 96 -- D.1.1 RESTATEMENT AS A RESULT OF PRIOR PERIOD ERRORS IDENTIFIED continued RECONCILIATION OF GROUP INCOME STATEMENT FOR THE YEAR ENDED 30 JUNE 20241 R million Group 30 June 2024 (previously reported) Item 1 Correction Increase/ (Decrease) Group 30 June 2024 Restated Insurance revenue 51 857 273 52 130 Insurance service expenses (46 145) 28 (46 117) Net income/(expenses) from reinsurance contracts (915) – (915) Insurance service result 4 797 301 5 098 Net financial result from insurance finance income and expense (7 245) (48) (7 293) – Net finance income/(expense) from insurance contracts (6 902) (48) (6 950) – Net finance income/(expense) from reinsurance contracts (343) – (343)– Net insurance and investment results 9 647 253 9 900 Net income 31 952 253 32 205 Operating profit 11 137 253 11 390 Profit before financing and income tax 12 134 253 12 387 Profit before income tax 10 011 253 10 264 Income tax expense (2 647) (68) (2 715) Profit for the year 7 364 185 7 549 Earnings per share for profit attributable to ordinary shareholders of the company during the year (cents): – Basic 1 082.7 27.6 1 110.3 – Diluted 1 076.3 27.4 1 103.7 1 Only the financial statement line items impacted by the adjustments have been included in this note; therefore, the note does not reproduce all line items from the Group income statement. RECONCILIATION OF GROUP STATEMENT OF OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 20241 R million Group 30 June 2024 (previously reported) Item 1 Correction Increase/ (Decrease) Group 30 June 2024 Restated Profit for the year 7 364 185 7 549 Net finance income/(expense) from insurance contracts issued 2 672 (971) 1 701 – Unrealised income/(expense) 3 595 (1 330) 2 265 – Tax on unrealised (income)/expense (923) 359 (564) Total income and expenses that will be reclassified to profit or loss when specific conditions are met 1 331 (971) 360 Other comprehensive income for the year, net of tax 1 348 (971) 377 Total comprehensive income for the year 8 712 (786) 7 926 1 Only the financial statement line items impacted by the adjustments have been included in this note; therefore, the note does not reproduce all line items from the Group statement of other comprehensive income. D. ADOPTION OF NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued 70 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 72 of 96 -- D.1.1 RESTATEMENT AS A RESULT OF PRIOR PERIOD ERRORS IDENTIFIED continued ITEM 2: CORRECTION OF THE NON-INSURANCE ACQUISITION COSTS FOR DISCOVERY INVEST During the year ended 30 June 2025, Discovery identified that it had not eliminated intragroup transactions for the reimbursement of the acquisition costs incurred within the SA Invest segment. This incorrect treatment resulted in an overstatement of both the fee income from administration business and non-insurance acquisition costs in the period ended 30 June 2024. The correction does not impact the Group income statement’s total profit, basic earnings per share, or diluted earnings per share. The restatement has had no impact on operating, investing, or financing cash flows. RECONCILIATION OF GROUP INCOME STATEMENT FOR THE YEAR ENDED 30 JUNE 20241 R million Group 30 June 2024 (post item 1correction) Item 2 Correction Increase/ (Decrease) Group 30 June 2024 Restated– Fee income from administration business 14 093 (497) 13 596 Non-insurance revenue and income 22 305 (497) 21 808 Net income 32 205 (497) 31 708 Non-insurance acquisition costs (988) 497 (491) Operating profit 11 390 – 11 390 Profit before financing and income tax 12 387 – 12 387 Profit before income tax 10 264 – 10 264 Income tax expense (2 715) – (2 715) Profit for the year 7 549 – 7 549 1 Only the financial statement line items impacted by the adjustments have been included in this note; therefore, the note does not reproduce all line items from the Group income statement. ITEM 3: GROUP STATEMENT OF CASH FLOWS Discovery regularly reviews its presentation and disclosures in line with evolving market practices, IFRS Accounting Standards, and changes in its business to enhance clarity and understanding. The Group has accordingly updated its statement of cash flows, applying the changes to the year ended 30 June 2025 and restating the prior year for comparability, with a reconciliation provided between the originally published 2024 figures and the restated balances. Previously, changes in ‘Fair value adjustments to liabilities under investment contracts’ and ‘Third-party interest: fair value adjustment to liabilities under investment contracts’ were recorded as cash outflows in Cash generated from operations with a corresponding entry within changes in operating liabilities. These fair value adjustments are now appropriately recognised as non-cash movements, with an equal and opposite change to the operating liabilities. In addition, the method for determining realised gains and losses on investments has been revised, and the prior year corrected accordingly. Importantly, the restatements have no impact on total ‘Cash flows from operating activities’, as reflected below. RECONCILIATION OF GROUP STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 20241 R million Group 30 June 2024 As previously published, including correction of item 1 as set out above Item 3 Correction Increase/ (Decrease) Group 30 June 2024 Restated Cash flow from operating activities 2 733 – 2 733 Cash generated by operations 3 250 726 3 976 Net movement in operating assets and liabilities 1 307 (726) 581 – Decrease in operating assets (7 513) 4 289 (3 224) – Increase in operating liabilities 8 820 (5 015) 3 805 1 Only the financial statement line items impacted by the adjustments have been included in this note; therefore, the note does not reproduce all line items from the Group statement. of cash flows. D. ADOPTION OF NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued 71 -- 73 of 96 -- SECTION E ACCOUNTING POLICIES 73 E.1 New Accounting Standards and amendments to published Accounting Standards not yet effective 73 E.2 Normalised headline earnings 74 E.3 Basis of preparation 72 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 74 of 96 -- E.1 NEW ACCOUNTING STANDARDS AND AMENDMENTS TO PUBLISHED ACCOUNTING STANDARDS NOT YET EFFECTIVE For the financial year commencing 1 July 2024, there were no material new standards, amendments and interpretations that became effective for Discovery, other than the IFRIC agenda decision relating to segment reporting. Refer to section A.1 Segment Information. Discovery has not early adopted any other IFRS Accounting Standards, amendments or interpretations that have been issued but not yet effective. Discovery does not expect any new IFRS Accounting Standards, amendments or interpretations that have been issued but not yet effective to have a material impact on the recognised amounts except for IFRS 18 Presentation and disclosure in Financial Statements (IFRS 18), which supersedes IAS 1 Presentation of Financial Statements (IAS 1) and provides additional requirements for the presentation and disclosure of information in the primary financial statements and the notes to improve transparency and comparability of information. For Discovery, IFRS 18 will be effective from 1 July 2027. Discovery is assessing additional disclosure requirements required. Interest Rate Benchmark Reforms (IBOR) In recent years, major interest rate benchmarks have been reformed globally, including the replacement of certain interbank offered rates (IBORs) with alternative nearly risk-free rates (referred to as “IBOR reform”). Discovery has financial instruments that have been or will be affected by these market-wide changes, most notably the transition from LIBOR to Sterling Overnight Index Average (SONIA) in the UK and the upcoming replacement of Johannesburg Interbank Average Rate (JIBAR) with South African Rand Overnight Index Average Rate (ZARONIA). JIBAR will be replaced by the ZARONIA. Following an observation period from 1 November 2022 to 31 October 2023, ZARONIA was identified and endorsed as JIBAR’s successor. The South African Reserve Bank (SARB) has indicated that JIBAR is expected to be discontinued by the end of 2026, with the official cessation date to be confirmed in December 2025. Several key milestones leading up to the cessation are outlined in the industry timeline published by the SARB, including: ■ November 2024 – ZARONIA-first for derivatives ■ June 2025 – ZARONIA-first for the cash market ■ March 2026 – No new JIBAR Discovery has the current following JIBAR-linked exposures as at 30 June 2025: ■ SA Bank borrowings, with associated interest rate derivatives, as detailed in Note A.5.2. ■ Investments of c. R7.8 billion. ■ Home loans provided to customers of c. R1.7 billion. Discovery will apply the same transition relief under IFRS Accounting Standards as it did when transitioning from LIBOR to SONIA. IBOR reforms generally result in changes to the basis for determining the contractual cash flows of financial assets and liabilities, including derivatives. For financial assets and liabilities measured at amortised cost, the entity will update the effective interest rate without recognising a gain or loss, provided that: ■ The change is a direct consequence of IBOR reform, and ■ The new basis for determining contractual cash flows is economically equivalent to the previous basis. For cash flow hedges, when assessing whether a forecast transaction remains highly probable, an entity will assume that the interest rate benchmark on which the hedged cash flows are based remains unchanged as a result of IBOR reform. E.2 NORMALISED HEADLINE EARNINGS Discovery assesses its performance using normalised headline earnings, an alternative profit measure not under the IFRS Accounting Standards, alongside its IFRS Accounting Standards profit measures. Management considers that Normalised Headline Earnings Per Share (NHEPS) is an appropriate alternative performance measure to enhance the comparability and understanding of the financial performance of the Group. Measures not in terms of IFRS Accounting Standards are not uniformly defined or used by all entities and may not be comparable with similarly labelled measures and disclosures provided by other entities. Discovery calculates headline earnings in accordance with the latest SAICA circular: ’Headline Earnings’. NHEPS is calculated by starting with headline earnings and adjusted to exclude material items that are not considered to be part of Discovery’s normal operations as follows: ■ Once-off transactions – for example, restructuring costs, transaction costs related to interest rate derivatives and initial deferred tax assets raised on previously unrecognised assessed losses ■ Unusual items – the Group considers items to be unusual when they have limited predictive value, or it is reasonable that items of a similar nature would not necessarily arise for several future reporting periods ■ Income or expenses not considered to be part of the Group’s normal operations – for example, amortisation of intangibles from business combinations and fair value gains or losses on foreign exchange contracts not designated as hedges Management is responsible for the calculation of NHEPS and determining the inclusions and exclusions in accordance with the policy. The Discovery Limited Audit Committee reviews the normalised headline earnings for transparency and consistency. E. ACCOUNTING POLICIES continued 73 -- 75 of 96 -- E.3 BASIS OF PREPARATION Statement of compliance Discovery Limited is a company incorporated in South Africa. The condensed consolidated annual financial statements for the year ended 30 June 2025 (annual results) consolidate the results of Discovery and its subsidiaries (together the Group) and equity account the Group’s interests in associates and joint ventures. The annual results comprise the Group statement of financial position at 30 June 2025, Group income statement, Group statement of other comprehensive income, Group statement of changes in equity and Group statement of cash flows for the year ended 30 June 2025 and selected explanatory notes. The condensed consolidated annual financial statements have been prepared in accordance with the JSE Limited (JSE) Listings Requirements, IFRS® Accounting Standards as issued by the International Accounting Standards Board (IFRS Accounting Standards), including IAS 34 Interim Financial Reporting (IAS 34), the South African Institute of Chartered Accountants (SAICA) Financial Reporting Guides as issued by the Accounting Practices Committee and Financial Pronouncements as issued by the Financial Reporting Standards Council (FRSC) and the requirements of the Companies Act of South Africa. The accounting policies adopted are consistent with the accounting policies applied in the prior annual financial statements. The financial information in these annual results has been extracted from the Group audited consolidated financial statements for the year ended 30 June 2025, but is not itself audited. As such, these annual results do not include all the notes typically included in the annual financial statements and must be read together with the Group audited consolidated financial statements for the year ended 30 June 2025. The Board of Discovery takes full responsibility for the accuracy of the extracted information. The Group audited consolidated financial statements for the year ended 30 June 2025 were audited by KPMG Inc. and Deloitte & Touche, who expressed an unmodified audit opinion. A copy of the set of Group audited consolidated financial statements with the signatures of the directors is available at the Company’s registered office through a secure electronic manner, at the election of the person requesting inspection. E. ACCOUNTING POLICIES continued 74 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 76 of 96 -- EMBEDDED VALUE STATEMENT 77 Table 1: Group embedded value 79 Table 2: Value of in-force covered business 79 Table 3: Group embedded value earnings 80 Table 4: Components of Group embedded value earnings 81 Table 5: Experience variances 82 Table 6: Methodology and assumption changes 83 Table 7: Value of new business 85 Table 8: Embedded value economic assumptions 87 Table 9: Embedded value sensitivity 87 Table 10: Value of new business sensitivity 75 -- 77 of 96 -- The embedded value of the Discovery Group consists of the following components: ■ the adjusted net worth attributed to the business at the valuation date; ■ plus: the present value of expected future shareholder cash flows from the in-force covered business; ■ less: the cost of required capital. The present value of expected future shareholder cash flows from the in-force covered business is calculated as the value of projected future after-tax shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate. The required capital are the assets attributed to the covered business above the amount required to back covered business liabilities, whose distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements. The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the new business written by the Discovery Group, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses and cost of required capital. The value of new business is calculated using the current reporting date assumptions. The embedded value includes the insurance and administration profits of the covered business in the Discovery Group. Covered business includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery Health (“Health”) and Discovery Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality Group, Ping An Health Insurance, Discovery Insure, Discovery Bank and Umbrella Funds, no published value has been placed on the current in-force business. In August 2011, the Discovery Group raised R800 million through the issue of non-cumulative, non-participating, non-convertible preference shares. For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth. Embedded value statement for the year ended 30 June 2025 76 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 78 of 96 -- TABLE 1: GROUP EMBEDDED VALUE R millions 30 June 2025 30 June 20241 % change Shareholders’ funds 65 699 54 451 21 Adjustment to shareholders’ funds from published basis2 (40 660) (35 163) 16 Adjusted net worth3 25 039 19 288 30 Value of in-force covered business before cost of required capital 104 812 94 258 11 Cost of required capital (3 297) (3 192) 3 Discovery Group embedded value 126 554 110 354 15 Number of shares (millions) 666.6 661.0 Embedded value per share 189.85 166.95 14 Diluted number of shares (millions) 668.7 665.0 Diluted embedded value per share4 189.25 165.94 14 1 “Shareholders’ funds” and “Adjustments to shareholders’ funds from published basis” have been restated as a result of prior period errors - refer to section D1.1 for more detail. The restatements do not affect the Group Embedded Value at 30 June 2024 as they relate to Life net assets under insurance contracts, which are eliminated on a consolidated embedded value basis. 2 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted using the closing exchange rate of R24.34/GBP (June 2024: R23.07/GBP). R millions 30 June 2025 30 June 2024 Life net assets under insurance contracts (21 333) (16 597) Vitality Life Limited net assets under insurance contracts (11 663) (11 314) VitalityHealth Insurance Acquisition Cash Flow (IACF) Asset (5 120) (4 351) VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) (7) (8) Goodwill relating to the acquisition of Standard Life Healthcare and the PAC joint venture (3 012) (2 855) Intangible assets (net of deferred tax) in covered businesses (813) (803) Net preference share capital (779) (779) Reversal of 1 Discovery Place IFRS 16 financial lease accounting 1 550 1 462 Equity settled share based payment mark-to-market adjustment* 517 82 (40 660) (35 163) * The “equity settled share based payment mark-to-market adjustment” reflects the difference between the provision in the IFRS equity and the mark-to-market value of the equity settled share based payments. Embedded value statement continued for the year ended 30 June 2025 77 -- 79 of 96 -- 3 The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the embedded value. R millions 30 June 2025 30 June 2024 Shareholders’ funds 65 699 54 451 Adjustment to shareholders’ funds (40 660) (35 163) Adjusted net worth 25 039 19 288 Excess of available capital over adjusted net worth 52 419 48 318 Available capital 77 458 67 606 Required capital 48 446 44 610 Excess available capital 29 012 22 996 The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth for embedded value purposes and the available capital on a statutory solvency basis for covered business. This includes: ■ The net preference share capital of R779 million which is included as available capital. ■ The difference between Vitality Life Limited’s Solvency UK Pillar 1 Own Funds and its adjusted net worth. ■ The difference between Life’s Pillar 1 Own Funds and its adjusted net worth. The following table sets out the required capital for each of the covered businesses: R millions 30 June 2025 30 June 2024 Health and Vitality 1 286 1 238 Life and Invest 29 349 27 935 VitalityHealth 4 761 4 138 VitalityLife 13 050 11 299 Total Required Capital 48 446 44 610 – For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost. – For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement. – For VitalityHealth, the required capital was set equal to 1.55 times the Solvency UK Pillar 1 Solvency Capital Requirement. – For VitalityLife, the required capital was set equal to 1.4 times the Solvency UK Pillar 1 Solvency Capital Requirement. 4 The diluted embedded value per share adjusts for the effect of vested treasury shares, share options exercised, and vesting of share awards where the impact is dilutive. This adjustment has been aligned to the diluted number of shares shown elsewhere in the financial statements. Embedded value statement continued for the year ended 30 June 2025 78 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 80 of 96 -- TABLE 2: VALUE OF IN-FORCE COVERED BUSINESS R millions Value before cost of required capital Cost of required capital Value after cost of required capital At 30 June 2025 Health and Vitality 27 972 (525) 27 447 Life and Invest1 42 869 (1 614) 41 255 VitalityHealth2 18 395 (526) 17 869 VitalityLife2 15 576 (632) 14 944 Total 104 812 (3 297) 101 515 At 30 June 2024 Health and Vitality 27 441 (527) 26 914 Life and Invest1 37 570 (1 757) 35 813 VitalityHealth2 14 353 (449) 13 904 VitalityLife2 14 894 (459) 14 435 Total 94 258 (3 192) 91 066 1 Included in the Life and Invest value of in-force covered business is R2 849 million (June 2024: R2 318 million) in respect of investment management services provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth. 2 The value of in-force has been converted using the closing exchange rate of R24.34/GBP (June 2024: R23.07/GBP). TABLE 3: GROUP EMBEDDED VALUE EARNINGS Year ended R millions 30 June 2025 30 June 2024 Embedded value at end of period 126 554 110 354 Less: embedded value at beginning of period (110 354) (98 176) Increase in embedded value 16 200 12 178 Dividends paid 1 707 1 269 Employee share option schemes (721) (683) Net change in capital 23 131 Transfer to hedging reserve 104 61 Acquisition of subsidiaries with non-controlling interest (1) (6) IFRS 17 impact on non-covered businesses1 – (2) Embedded value earnings 17 312 12 948 Annualised return on opening embedded value 15.7% 13.2% 1 In respect of 30 June 2024, the opening embedded value for that period (30 June 2023) was not restated for the transition to IFRS 17. This item represents the difference between IFRS 4 and IFRS 17 equity on non-covered business, such as Discovery Insure and Ping An Health Insurance, and an opening IFRS balance sheet restatement as a result of prior period errors. These impacts were not included in the embedded value earnings for 30 June 2024 and so a minor adjustment was required to reconcile the change from the embedded value at the beginning of the period. Embedded value statement continued for the year ended 30 June 2025 79 -- 81 of 96 -- TABLE 4: COMPONENTS OF GROUP EMBEDDED VALUE EARNINGS Year ended 30 June 2025 Year ended 30 June 2024 R millions Net worth Cost of required capital Value of in-force covered business Embedded value Embedded value Total profit from new business (at point of sale) (6 609) (300) 9 063 2 154 1 832 Profit from existing business – Expected return 8 856 (25) 2 047 10 878 10 340 – Change in methodology and assumptions1 4 169 162 (4 735) (404) 2 385 – Experience variances 331 113 2 461 2 905 564 Impairment, amortisation and fair value adjustment2 (62) – – (62) (60) Increase in goodwill and intangibles (382) – – (382) (308) Non-covered businesses3 2 537 – – 2 537 1 088 Non-recurring expenses (355) – – (355) (96) Acquisition costs4 (45) – – (45) (33) Finance costs5 (3 125) – – (3 125) (2 796) Foreign exchange rate movements6 (113) (57) 1 720 1 550 (1 555) Other7 (8) – – (8) 2 Return on shareholders' funds5,8 1 669 – – 1 669 1 585 Embedded value earnings 6 863 (107) 10 556 17 312 12 948 1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the operating and economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to previous embedded value statements). 2 This item reflects the amortisation of the intangible assets reflecting the banking costs, Cambridge Mobile Telematics system spend and capital expenditure in Vitality Global. 3 This item includes the profits of non-covered businesses. Head office costs which relate to non-covered business are included in this item, as well as cR171 million of expenses which are currently incurred by the covered businesses but will be met by non-covered businesses in due course, and hence have not been included in the relevant covered businesses’ embedded value expense analysis. For June 2025, profits of non-covered segments within the covered businesses of cR267 million, which were previously reported as experience variances have been included in this item. 4 Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has been written over the period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value of new business and therefore the costs are not deducted from the value of new business. 5 Finance costs and return on shareholders’ funds are shown gross of intercompany charges (R1 351 million at 30 June 2025 and R1 046 million at 30 June 2024). 6 This item includes foreign exchange gains / (losses) emerging through the income statement, in addition to translation impacts on the cost of required capital and value of in-force. 7 This item includes, among other items, the tangible tax impact from movements in covered business intangible assets, which are excluded from the net worth. 8 The return on shareholders’ funds is shown net of tax and management charges. Embedded value statement continued for the year ended 30 June 2025 80 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 82 of 96 -- TABLE 5: EXPERIENCE VARIANCES Health and Vitality Life and Invest VitalityHealth VitalityLife Year ended 30 June 2025 Year ended 30 June 2024 R millions Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force Net worth Value of in- force Total Total Renewal expenses 15 – (24) 6 (12) – 40 – 25 (55) Lapses and surrenders1 12 (255) 80 227 – 1 524 (172) 167 1 583 508 Mortality and morbidity2 – – 848 (68) (1 204) – (38) – (462) (681) Policy alterations3 – (1) (562) (27) – – 19 (190) (761) (669) Backdated cancellations – – – – – – – – – – Premium and fee income2 119 – 14 179 814 – (45) 19 1 100 754 Inflation-linked indexation4 – – (13) (218) – – 8 93 (130) (152) Economic5 – – (74) 592 198 – 3 – 719 269 Tax6 130 – 200 (159) (19) – 308 23 483 147 Reinsurance7 – – – – – – (162) 68 (94) (184) Maintain modelling term8 – 339 – 93 – 134 – – 566 546 Vitality benefits9 (107) – – – – – (9) – (116) (186) Other – (1) (12) 38 – – (24) (9) (8) 267 Total 169 82 457 663 (223) 1 658 (72) 171 2 905 564 1 For Health and Vitality, the lapse and surrender experience was driven by the impact of employer groups who have widened the eligible schemes that employees can join beyond the Discovery Health Medical Scheme. For VitalityHealth, the lapse and surrender experience reflects improved retention rates and higher achieved premium increases. 2 For Life and Invest, overall claims experience for the period was better than expected for Individual Life, Group Life and Invest lines of business. For VitalityHealth, this item reflects the difference between the assumed long-term margin for embedded value purposes and the net impact of increasing claims and the associated increased risk premiums. In light of this, and expected future trends, VitalityHealth have updated their embedded value margin and premium run-off assumptions as part of their periodic review of the embedded value basis. 3 For Life and Invest, and VitalityLife, the policy alterations experience relates mainly to persistent pressures within the economic environment. This is partially offset by positive experience on lapses and premium income. 4 For Life and Invest, the experience reflects lower than expected CPI increases on inflation-linked policies on the Individual Life business. 5 For Life and Invest, better than expected unit fund growth in Invest resulted in an improved projected fee income reflected in the value of in-force. For VitalityHealth, investment return continued to contribute to profitability as interest rates in the UK remain high. 6 The tax variance arises due to the timing difference between the expected tax payments and actual payments. 7 For VitalityLife, the reinsurance experience reflects the better-than-expected retention in the business and higher in-period inflation, which resulted in higher reinsurance premiums, as well as an increase in provisions related to prior periods. 8 For Health and Vitality, Life and Invest, and VitalityHealth, the projection term is rebased at each reporting period. Therefore, an experience variance arises because the total term of the in-force covered business is effectively increased by twelve months. 9 For Health and Vitality, the experience is driven by higher benefit costs and utilisation in the Vitality business. Embedded value statement continued for the year ended 30 June 2025 81 -- 83 of 96 -- TABLE 6: METHODOLOGY AND ASSUMPTION CHANGES Health and Vitality Life and Invest VitalityHealth VitalityLife Year ended 30 June 2025 Year ended 30 June 2024 R millions Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force Total Total Modelling changes1 – (51) 96 (26) – – (10) (108) (99) 2 289 Expenses2 – (267) (23) (87) – – – – (377) (34) Lapses3 – (251) – (345) – – (376) (325) (1 297) (652) Mortality and morbidity4 – – (141) 262 – 487 99 327 1 034 (501) Benefit changes – 17 – – – – – – 17 (57) Vitality – – – – – – – – – – Tax – – – – – – – – – – Economic assumptions5 – (1 542) – 1 116 – – 536 64 174 (411) Premium and fee income6 – 472 – (276) – – – – 196 198 Reinsurance and financing7 – – 647 (363) – – 3 008 (3 188) 104 404 Other8 – (1) 28 (201) – – 305 (287) (156) 1 149 Total – (1 623) 607 80 – 487 3 562 (3 517) (404) 2 385 1 Minor refinements to the modelling environment were introduced. 2 For Health and Vitality, and Life and Invest, the expense assumptions were updated to align to budget. 3 For Health and Vitality, a one-year stressed lapse assumption was implemented to manage expected short term negative variation, allowing time for specific interventions to take effect. For Life and Invest, the lapse basis for certain plan types was strengthened in line with internal investigations. For VitalityLife, the item includes a strengthening of the PAC business lapse basis and VitalityLife servicing assumptions. 4 For Life and Invest, refinements to the mortality and morbidity assumptions on the Individual Life business and changes to the interest on lump sum claims reserves on the Group Life business were implemented. For VitalityHealth, the Margin and Annuity Factor assumptions were revised to align to recent experience and forward-looking expectations. For VitalityLife, the item reflects a strengthening of the mortality basis, which is more than offset by a weakening of the morbidity basis, to be more in line with experience. 5 For Health and Vitality, and Life and Invest, the item includes the impact of updating the internally derived yield curves as at 30 June 2025. For Health and Vitality, this also includes the impact of lower-than-expected inflation applicable to the administration and managed care fee escalation in 2025. For VitalityLife, this item includes the impact of updating the assumptions relative to the Solvency UK yield curves and the IFRS interest rates. 6 For Health and Vitality, this item represents an additional administration and managed care fee margin effective for 2025. This additional margin is contractually effective given a defined level of spend to enhance the services rendered by the administrator. For Life and Invest, this item includes assumption changes relating to Vitality status progressions, decrement rates and integration benefits applied in the shared value model. 7 For Life and Invest, the reinsurance and financing item primarily relates to the impact of internal financing arrangements, where the future expected cash flows arising from part of the negative reserves are monetised to match other positive policy liabilities. For VitalityLife, this item includes the impact of external financing arrangements, where future expected cash flows arising from part of the negative reserves are monetised to partially fund new business and support liquidity needs in the business. 8 For Life and Invest, this item mainly relates to a portion of the IAS12 deferred tax liability that has now been recognized in the embedded value. For VitalityLife, the discretionary margin on the PAC IFRS 4 reserves was removed in line with basis changes approved on the PAC book of business. This item also includes an increase to the cost of capital for VitalityLife, driven by a reduced allowance for the loss absorbing capacity of deferred taxes on required capital. Embedded value statement continued for the year ended 30 June 2025 82 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 84 of 96 -- TABLE 7: VALUE OF NEW BUSINESS Year ended R millions 30 June 2025 30 June 2024 % change Health and Vitality Gross profit from new business (at point of sale) 1 095 1 103 Cost of required capital (45) (52) Present value of future profits from new business (at point of sale) after cost of required capital 1 050 1 051 0 New business annualised premium income1 6 093 7 716 (21) Life and Invest Present value of future profits from new business (at point of sale)2 535 560 Cost of required capital (74) (79) Present value of future profits from new business (at point of sale) after cost of required capital 461 481 (4) New business annualised premium income3 3 270 3 214 2 Annualised profit margin4 1.8% 2.0% Annualised profit margin excluding Invest business 2.1% 3.8% VitalityHealth5 Present value of future profits from new business (at point of sale) 671 491 Cost of required capital (62) (63) Present value of future profits from new business (at point of sale) after cost of required capital 609 428 42 New business annualised premium income6 2 564 2 443 5 Annualised profit margin4 3.1% 2.6% VitalityLife Present value of future profits from new business (at point of sale) 153 (58) Cost of required capital (119) (70) Present value of future profits from new business (at point of sale) after cost of required capital 34 (128) 127 New business annualised premium income7 2 094 1 462 43 Annualised profit margin4 0.2% (1.3%) 1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income shown above excludes premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums in respect of new business written during the period but only activated after 30 June 2025. The total Health and Vitality new business annualised premium income written over the period was R10 119 million (June 2024: R11 481 million, which included the onboarding of the Sasolmed medical scheme). 2 Included in the Life and Invest embedded value of new business is R49 million (June 2024: R15 million) in respect of investment management services provided on off balance sheet investment business. Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the impact of which has been recognised in the value of new business. 3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium is due after the valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded after receipt. Invest new business also includes Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the reporting period, including policies whose first premium is due after the valuation date. The new business annualised premium income of R3 270 million (single premium APE: R1 717 million (June 2024: R1 545 million)) shown above excludes automatic premium increases, servicing increases in respect of existing business and Umbrella Funds new business annualised premium income. The total new business annualised premium income written over the period was R6 633 million (single premium APE: R1 806 million (June 2024: R1 626 million)) and is set out in the table below: R millions 30 June 2025 30 June 2024 New business annualised premium income 3 270 3 214 Automatic premium increases 2 219 2 249 Servicing increases 761 779 Umbrella Funds new business annualised premium income 383 626 Total new business annualised premium income 6 633 6 868 Single premium Invest business is included at 10% of the value of the single premium. Section 14 transfers for Umbrella Funds are included at 10% of the fund value. Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans, are shown in Table 5 as experience variances and not included as new business. Term extensions on existing contracts are not included as new business. 4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums. 5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date multiplied by the Margin multiplied by the Annuity Factor plus the new business cash flows from point of sale to the valuation date. The assumptions for the Margin and Annuity Factor are shown in Table 8. 6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised premium income shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month, as well as premiums in respect of new business written during the period but only activated after 30 June 2025. 7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first premium is due after the valuation date. Embedded value statement continued for the year ended 30 June 2025 83 -- 85 of 96 -- BASIS OF PREPARATION TABLE 8: EMBEDDED VALUE ECONOMIC ASSUMPTIONS R millions 30 June 2025 30 June 2024 Beta coefficient 0.75 0.75 Equity risk premium (%) 3.5 3.5 Risk discount rate (%) – Health and Vitality1 13.875 14.875 – Life and Invest1 14.625 15.375 – VitalityHealth 6.573 6.573 – VitalityLife 6.734 6.495 Rand / GB Pound Exchange Rate Closing 24.34 23.07 Average 23.48 23.55 Margin over Expense inflation to derive medical inflation (%) South Africa 3.00 3.00 Expense inflation (%)2 South Africa – Health and Vitality 5.66 6.87 – Life and Invest 6.41 7.05 United Kingdom 3.72 4.01 Pre-tax investment return (%) South Africa – Cash 1 10.5 11.25 – Life and Invest bonds3 12 12.75 – Health and Vitality bonds3 11.25 12.25 – Equity 15.50 16.25 United Kingdom – VitalityHealth risk-free rate 3.95 3.95 – VitalityLife risk-free rate 4.11 3.87 – VitalityLife Investment return 5.26 4.91 Long-term corporation tax rate (%) South Africa 27 27 United Kingdom 25 25 VitalityHealth Margin and Annuity Factor assumptions – Margin (net of tax and cost of required capital) (%) 10.56 12.35 – Annuity Factor 7.81 6.42 Projection term – Health and Vitality 20 years 20 years – Discovery Life 40 years 40 years – Group Life 20 years 20 years – VitalityLife No cap No cap – VitalityHealth4 20 years 20 years 1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds. 2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow weighted average inflation is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the long-term market view of inflation. 3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown. 4 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor. Embedded value statement continued for the year ended 30 June 2025 84 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 86 of 96 -- The Discovery Group embedded value is calculated based on a risk discount rate using the Capital Asset Pricing Model (CAPM) approach with specific reference to the Discovery Group beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk discount rate proxies the result of a Weighted Average Cost of Capital approach with reference to the capital structure of the Group and the observed beta calculated using daily returns over a long time period. The observed beta is calculated with reference to the ALSI. The assumed beta will only change if the capital structure of the Group and/or the observed beta calculated using daily returns over a long time period suggest the beta assumption should depart significantly from the assumption at the financial year-end. As beta values reflect the historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available, augmented by reinsurance and industry information. The Health and Vitality lapse assumptions were derived from the results of recent experience investigations. The VitalityHealth assumptions were derived from internal experience and augmented by future expectations. VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery Group information. Renewal expense assumptions were based on the results of the latest expense and budget information. The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding expenses of an exceptional or non-recurring nature. The South African investment return assumptions for Life, Invest, Health and Vitality were set relative to an internally derived nominal yield curve, which is consistent with the IFRS 17 reporting basis. The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining the net investment return assumption. The risk-free rate assumption for VitalityHealth was based on the single interest rate derived from the Prudential Regulatory Authority yield curve. VitalityLife has transitioned to the use of full yield curves to represent its risk-free rate assumption following the implementation of IFRS 17. For consistency, VitalityLife has also transitioned to the use of a market inflation curve from a long-term market view of inflation. VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by the Margin multiplied by the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed future lapse rates and premium increases. The Margin assumption reflects assumed profit margins after tax and the cost of required capital. The assumptions underlying the Annuity Factor and Margin are set at the total book level, taking into account the current experience and future expectations across all durations of in-force business. The economic components underlying the Annuity Factor are reviewed at each reporting date; the non- economic components underlying the Annuity Factor and Margin assumptions are reviewed periodically. The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on tangible assets. The Vitality Life Limited required capital amount is assumed to earn the investment return assumption, which is set based on the return on a portfolio of government and corporate bonds assumed to back the required capital. The Life and Invest cost of required capital is calculated assuming shareholder cash flow is limited to the cash flow available after having met both the required capital amount and an internally defined liquidity target capital requirement of tangible assets. The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”) 107: Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to take into account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 2. Embedded value statement continued for the year ended 30 June 2025 85 -- 87 of 96 -- BASIS OF PREPARATION The risk discount rate uses the CAPM approach with specific reference to the Discovery Group beta coefficient. As beta values reflect the historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. The sensitivity of the embedded value and the embedded value of new business at 30 June 2025 to changes in the risk discount rate is included in the tables below. For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for management action such as risk premium increases where future experience is worse than the base assumptions. TABLE 9: EMBEDDED VALUE SENSITIVITY Discovery Group Health and Vitality R millions Adjusted net worth Value of in-force Cost of required capital Base 25 039 27 972 (525) Impact of: Risk discount rate + 1% 25 039 26 448 (570) Risk discount rate – 1% 25 039 29 656 (475) Lapses – 10% 24 873 28 893 (551) Interest rates – 1%1 25 211 27 859 (506) Equity and property market value – 10% 24 981 27 972 (525) Equity and property return + 1% 25 039 27 972 (525) Renewal expenses – 10% 25 150 30 731 (486) Mortality and Morbidity – 5% 25 333 27 972 (525) Projection term + 1 year 25 039 28 284 (530) 1 All economic assumptions were reduced by 1%. The following table shows the effect of using different assumptions on the embedded value of new business. TABLE 10: VALUE OF NEW BUSINESS SENSITIVITY Health and Vitality R millions Value of in-force Cost of required capital Base 1 095 (45) Impact of: Risk discount rate + 1% 1 006 (49) Risk discount rate – 1% 1 192 (40) Lapses – 10% 1 172 (49) Interest rates – 1%1 1 102 (43) Equity and property return + 1% 1 095 (45) Renewal expenses – 10% 1 259 (42) Mortality and Morbidity – 5% 1 095 (45) Projection term + 1 year 1 112 (45) Acquisition expenses – 10% 1 132 (45) 1 All economic assumptions were reduced by 1%. Embedded value statement continued for the year ended 30 June 2025 86 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 88 of 96 -- Life and Invest VitalityHealth VitalityLife Embedded value % change Value of in-force Cost of required capital Value of in-force Cost of required capital Value of in-force Cost of required capital 42 869 (1 614) 18 395 (526) 15 576 (632) 126 554 39 409 (1 715) 17 337 (684) 14 505 (720) 119 049 (6) 46 923 (1 496) 19 574 (346) 16 806 (499) 135 182 7 46 523 (1 687) 20 621 (589) 16 586 (717) 133 952 6 43 522 (1 566) 19 574 (559) 14 994 (745) 127 784 1 41 937 (1 602) 18 395 (526) 15 576 (632) 125 576 (1) 43 299 (1 604) 18 395 (526) 15 576 (632) 126 994 0 43 625 (1 580) 20 251 (526) 15 920 (613) 132 472 5 45 642 (1 508) 22 204 (526) 16 087 (607) 134 072 6 42 943 (1 616) 18 618 (532) 15 576 (632) 127 150 0 Life and Invest VitalityHealth VitalityLife Value of new business % change Value of in-force Cost of required capital Value of in-force Cost of required capital Value of in-force Cost of required capital 535 (74) 671 (62) 153 (119) 2 154 362 (79) 535 (78) (37) (134) 1 526 (29) 734 (69) 823 (42) 369 (95) 2 872 33 727 (77) 1 027 (72) 364 (137) 2 955 37 543 (72) 823 (66) 268 (136) 2 419 12 567 (74) 671 (62) 153 (119) 2 186 1 578 (72) 862 (62) 221 (116) 2 628 22 613 (69) 1 063 (62) 215 (116) 2 694 25 539 (74) 697 (62) 153 (119) 2 201 2 718 (74) 784 (62) 396 (119) 2 730 27 87 -- 89 of 96 -- ANNEXURE A 89 New business annualised premium income 90 Income from non-insurance business lines 90 Cash conversion ratio 88 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 90 of 96 -- This Annexure does not form part of the IFRS results. Discovery assesses its performance using alternative non-IFRS profit and income measures. These measures enhance the comparability and understanding of the financial performance of the Group. NEW BUSINESS ANNUALISED PREMIUM INCOME for the year ended 30 June 2025 The new business annualised premium income (API) set out below provides a view of the scale of new business across all operations of the Group and does not necessarily reflect the new business attributable to the legal entities within the Group. For instance, DHMS new business is attributable to the medical scheme but is under the administration and marketing of Discovery Health which earns a fee in respect of such services. New business API, decreased by 2% for the year ended 30 June 2025 when compared to the corresponding prior period. Group 2025 Group 2024 % Change Discovery Health1 9 573 11 069 (14%) Discovery Life 3 203 3 568 (10%) Individual Life 2 733 2 778 (2%) Group Life 87 164 (47%) Discovery Umbrella 383 626 (39%) Discovery Invest 3 430 3 300 4% Discovery Insure 1 361 1 388 (2%) Discovery Vitality 546 412 33% New business API from Discovery SA 18 113 19 737 (8%) VitalityHealth2 2 851 2 779 3% VitalityLife 2 499 1 956 28% Ping An Health Insurance (PAHI) own licence 3 023 2 486 22% New business API from Vitality 8 373 7 221 16% Total new business API of Group excluding products in run down or discontinued3 26 486 26 958 (2%) 1 New business API for Discovery Health includes new business API for all businesses administered by Discovery Health, including DHMS, Closed Schemes and offerings such as Gap cover and FlexiCare cover. Closed Schemes refer to those restricted to certain employers and industries. In the corresponding prior year, Discovery Health secured the administration of Sasolmed Medical Scheme. Excluding Sasolmed, new business API increased 12%. 2 VitalityHealth has amended the new business definition to include expansions of existing business. The comparative VitalityHealth API has been restated. This has been done to align to Discovery Health. 3 Products in run down or discontinued include Discovery Insure Commercial and PAHI reinsurance business. The comparative API has been restated to exclude Discovery Insure Commercial given the decision to exit this market with cover ceasing on 31 August 2024. CALCULATION OF NEW BUSINESS API New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of new single premium policies. It also includes both automatic premium increases and servicing increases on existing long-term insurance policies. The amounts exclude indirect taxes. The new business API in the table above differs from the new business API disclosed in the embedded value largely as a result of: ■ The timing of inclusion of the policyholders in the calculation of new business API – in the embedded value, new business is included from the earlier of the date that the first premium has been received or when the policy is on risk, whereas in the table above, new business is included when the policy has been contractually committed. ■ Inclusion of automatic premium increases and servicing increases on existing life policies – these are included in the table above but excluded in the embedded value API values disclosed. Refer to the footnotes to Table 7: Embedded Value of New Business for a more detailed description of the differences in new business disclosures between the embedded value and the table above. Annexure A 89 -- 91 of 96 -- INCOME FROM NON-INSURANCE BUSINESS LINES for the year ended 30 June 2025 The table below includes income from business lines and activities not covered by the new business API definition, as outlined in the previous table. For Discovery Bank, banking fees and commissions are presented net of related expenses. This information differs from that provided in note A.4, which reflects the gross revenue streams for goods or services within the scope of IFRS 15 Revenue from Contracts with Customers. Group 2025 Group 2024 Change % Discovery Health – Income excluded from API measure 1 343 1 260 7% Discovery Bank 2 338 1 818 29% Discovery Bank – Net banking fee and commission income (NIR)1 1 373 1 039 32% Discovery Bank – Net bank interest and similar income (NII) 965 779 24% Vitality Global income2 2 962 2 828 5% Vitality Network 1 977 1 894 4% Vitality Health International (excluding PAHI) 985 934 5% Total income from non-insurance business lines 6 643 5 906 12% 1 Refer to A.1 Segment Information. 2 Vitality Global income includes gross recurring and lump sum revenues earned by Vitality Group and solutions revenue from external clients, while that from internal clients and rewards is specifically excluded. CASH CONVERSION RATIO For the year ended 30 June 2025 Cash conversion is calculated as Operating Cash Flow (per the Group shareholder free cash movement included in the additional analyst information on Discovery’s website), divided by Normalised profit from operations (IFRS total) net of Income tax expense (IFRS total) per A.1 Segment Information. The Operating Cash Flow includes the net impact of funding sourced from financial reinsurance (whether securitised from new business or the in-force book), which offsets new business acquisition costs, and the in-period repayments in respect of previous funding taken. Group 2025 Group 2024 Change % Cash conversion ratio 76.7% 65% –% The cash conversion ratio for the prior year has been restated for the correction of prior period errors as disclosed in D.1.1 and for changes to segment disclosure (refer A.1 Segment Information “Changes from 1 July 2024"). Annexure A continued 90 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 92 of 96 -- ANNEXURE B 92 Impact of corrections on normalised profit from operations for the six months ended 31 December 2024 Annexure B 91 -- 93 of 96 -- IMPACT OF CORRECTIONS ON NORMALISED PROFIT FROM OPERATIONS FOR THE SIX MONTHS ENDED 31 DECEMBER 2024 NORMALISED PROFIT FROM OPERATIONS The table below presents the estimated corrected results for the prior period error described in note D.1, for the six months ended 31 December 2024: Updated As previously published in March 2025 R million Group December 2024 Unaudited Group December 2024 Unaudited Change Discovery Life 2 686 2 612 74 Discovery Invest 971 904 67 Other Discovery SA operations 2 030 2 004 26 Normalised profit from Discovery SA 5 687 5 520 167 Normalised profit from Vitality 1 500 1 500 – Normalised profit from operations 7 187 7 020 167 TOTAL EQUITY Updated As previously published in March 2025 R million Group December 2024 Unaudited Group December 2024 Unaudited Change Equity attributable to equity holders of the Company 61 040 64 647 (3 607) Non-controlling interest (3) (3) – Total equity 61 037 64 644 (3 607) Annexure B continued 92 DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 -- 94 of 96 -- Transfer secretaries Computershare Investor Services (Pty) Limited (Registration number: 2004/003647/07) Rosebank Towers, 15 Biermann Avenue, Rosebank, 2196 Private Bag X9000, Saxonwold, 2132 Sponsors and debt sponsors Nedbank Corporate and Investment Banking, a division of Nedbank Limited Secretary and registered office AC Ceba (FCG) (F.Inst D) Discovery Limited (Incorporated in the Republic of South Africa) (Registration number: 1999/007789/06) Company tax reference number: 9652/003/71/7 JSE share code: DSY ISIN: ZAE000022331 JSE share code: DSBP ISIN: ZAE000158564 JSE bond company code: DSYI 1 Discovery Place, Sandton, 2196 PO Box 786722, Sandton, 2146 Tel: (011) 529 2888 Fax: (011) 539 8003 Directors ME Tucker (UK) (Chairperson), A Gore* (Group Chief Executive), LM Chiume, VN Fakude1 R Farber, WM Hlahla, FN Khanyile, D Macready, KC Ramon, M Schreuder, B Swartzberg*, BA van Kralingen, DM Viljoen* (Group Chief Financial Officer). * Executive. 1 Appointed effective 1 September 2025 Debt officer DM Viljoen Annual financial results – prepared by G Pieterse CA(SA), J Symons CA(SA) – supervised by DM Viljoen CA(SA) Embedded value statement – prepared by P Bolink FASSA – supervised by A Rayner FASSA, FIA Administration 93 -- 95 of 96 -- Discovery Limited | +27 11 529 2888 | askthecfo@discovery.co.za | www.discovery.co.za Copyright 2025. Discovery Ltd is the licensed controlling company of the designated Discovery Insurance Group. -- 96 of 96 --